

BEST AVAILABLE COPY

H3100 PCT JS

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
9 December 2004 (09.12.2004)

PCT

(10) International Publication Number
WO 2004/106381 A1

- (51) International Patent Classification⁷: C07K 16/28, A61K 39/395, A61P 35/00, 35/02, 19/02
- (21) International Application Number:
PCT/EP2004/005685
- (22) International Filing Date: 26 May 2004 (26.05.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
03012136.2 31 May 2003 (31.05.2003) EP
- (71) Applicant (*for all designated States except US*): MICROMET AG [DE/DE]; Staffelseestr. 2, 81477 Munich (DE).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): KUFER, Peter [DE/DE]; Am Kapellenacker 13, 85368 Moosburg (DE). LUTTERBÜSE, Ralf [DE/DE]; Schröfelhofstr. 35, 81375 München (DE). KOHLEISEN, Birgit [DE/DE]; Staffelseestr. 2, 81477 München (DE). ZEMAN, Steven [US/DE]; Maria-Birnbaumstr. 4, 80686 Munich (DE). BÄUERLE, Patrick [DE/DE]; Waldpromenade 18C, 82131 Gauting (DE).
- (74) Agent: VOSSIUS & PARTNER; Siebertstrasse 4, 81675 Munich (DE).
- (81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIGO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/106381 A1

(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTI-CD3, ANTI-CD19 ANTIBODY CONSTRUCTS FOR THE TREATMENT OF B-CELL RELATED DISORDERS

(57) Abstract: The present invention relates to a pharmaceutical composition comprising a bispecific single chain antibody construct, said bispecific single chain antibody construct comprising binding domains specific for human CD3 and human CD19, wherein the corresponding variable heavy chain regions (V_H) and the corresponding variable light chain regions (V_L) regions are arranged, from N-terminus to C-terminus, in the order, V_H (CD19)- V_L (CD19)- V_H (CD3)- V_L (CD3), V_H (CD3)- V_L (CD3)- V_H (CD19)- V_L (CD19) or V_H (CD3)- V_L (CD3)- V_L (CD19)- V_H (CD19). Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CD19 antigen are disclosed.

PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTI-CD3, ANTI-CD19
ANTIBODY CONSTRUCTS FOR THE TREATMENT OF B-CELL RELATED DISORDERS

The present invention relates to a pharmaceutical composition comprising a bispecific single chain antibody construct, said bispecific single chain antibody construct comprising binding domains specific for human CD3 and human CD19, wherein the corresponding variable heavy chain regions (V_H) and the corresponding variable light chain regions (V_L) are arranged, from N-terminus to C-terminus, in the order, $V_H(CD19)-V_L(CD19)-V_H(CD3)-V_L(CD3)$, $V_H(CD3)-V_L(CD3)-V_H(CD19)-V_L(CD19)$ or $V_H(CD3)-V_L(CD3)-V_L(CD19)-V_H(CD19)$. Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CD19 antigen are disclosed.

Despite the medical importance, research in B-cell mediated diseases such as non-Hodgkin lymphoma has produced only a small number of clinically usable data and conventional approaches to cure such diseases remain tedious and unpleasant and/or have a high risk of relapse. For example, although high dose chemotherapy as a primary treatment for high grade non-Hodgkin lymphoma may improve overall survival, about 50% of the patients still die of this disease (Gianni, N Engl. J. Med. 336 (1997), 1290-7; Urba, J. Natl. Cancer Inst. Monogr. (1990), 29-37; Fisher, Cancer (1994)). Moreover, low-grade non-Hodgkin lymphoma-like chronic lymphatic leukemia and mantle cell lymphoma are still incurable. This has stimulated the search for alternative strategies such as immunotherapy. Antibodies directed against cell surface molecules defined by CD antigens represent a unique opportunity for the development of therapeutic reagents. The expression of certain CD antigens is highly restricted to specific lineage lymphohematopoietic cells and over the past several years, antibodies directed against lymphoid-specific antigens have been used to develop treatments that were effective either in vitro or in vivo animal models (Bohlen, Blood 82 (1993), 1803-121; Bohlen, Cancer Res 53 (1993), 18: 4310-4; Bohlen, Cancer Res 57 (1997), 1704-9; Haagen, Clin Exp Immunol 90 (1992), 368-

75; Haagen, Cancer Immunol Immunother. 39 (1994), 391-6; Haagen, Blood 84 (1994), 556-63; Haagen, Blood 85 (1995), 3208-12; Weiner, Leuk Lymphoma 16 (1995), 199-207; Csoka, Leukemia 10 (1996), 1765-72.). In this respect CD19 has proved to be a very useful target. CD19 is expressed in the whole B lineage from the pro B cell to the mature B cell, it is not shed, is uniformly expressed on all lymphoma cells, and is absent from stem cells (Haagen, Clin Exp Immunol 90 (1992), 368-75; Uckun, Proc. Natl. Acad. Sci. USA 85 (1988), 8603-7). An interesting modality is the application of a bispecific antibody with one specificity for CD19 and the other for the CD3 antigen on T cells. However, bispecific antibodies thus far available suffer from low T-cell cytotoxicity and the need of costimulatory agents in order to display satisfactory biological activity. The CD3 complex denotes an antigen that is expressed on T-cells as part of the multimolecular T-cell receptor complex. It consists of several different chains for instance γ , δ , ϵ , ζ or/and η chains. Clustering of CD3 on T cells, e.g., by immobilized anti-CD3-antibodies, leads to T cell activation similar to the engagement of the T cell receptor but independent from its clone typical specificity. Actually, most anti-CD3-antibodies recognize the CD3 ϵ -chain.

Prior art has exemplified T cell activation events employing antibody molecules. For example, US 4,361,549 proposes a hybrid cell line for the production of monoclonal antibody to an antigen found on normal human T cells and cutaneous T lymphoma cells and defines the antibody produced as "OKT3". In US 5,885,573 the murine OKT3 (described in US 4,361,549) has been transferred into a human antibody framework in order to reduce its immunogenicity. Furthermore, US 5,885,573 discloses specific mutations in the Fc receptor ("FcR")-binding segment of OKT-3 which leads to a Glu at position 235, a Phe at position 234 or a Leu at position 234, i.e. to specific mutations in the CH2 region which are supposed to result in modified binding affinities for human FcR. In proliferation assays or in assays relating to the release of cytokines, the mutated OKT-3 antibodies disclosed in US 5,885,573 appear to result in comparable cell proliferations to that observed with PBMC stimulated with the original murine OKT3 and to similar amounts of cytokines produced. Merely the mutated Glu-235 mAb induced smaller quantities of TNF- α and GM-CSF and no IFN- γ . No T cell proliferation was induced by Glu-235 monoclonal antibody ("mab") using PBMC from three different donors at mab concentrations up to 10 μ g/ml, suggesting that the alteration of the FcR binding region of this mab had

impaired its mitogenic properties. T cell activation by Glu-235 mab also resulted in lower levels of expression of surface markers Leu23 and IL-2 receptor. US 5,929,212 discloses a recombinant antibody molecule in which the binding regions have been derived from the heavy and/or light chain variable regions of a murine anti-CD3 antibody, e.g. OKT3, and have been grafted into a human framework. WO 98/52975 discloses a mutated variant of the murine anti-CD3 antibody OKT3. The mutated OKT3 antibody is produced using a recombinant expression system and WO 98/52975 proposes that the mutated anti-CD3 antibody is more stable than the parental OKT3 protein during extended storage periods. US 5,955,358 discloses a method of shuffling, at the DNA level, multiple complementarity determining ("CDR") domains, either from the same or different antibodies, meaning that their order within antibody variable domains is altered to yield new combinations of binding regions.

OKT3 has been used as potent immunosuppressive agent in clinical transplantation to treat allograft rejection (Thistlethwaite 1984, Transplantation 38, 695-701; Woodle 1991, Transplantation 51, 1207-1212; Choi 2001, Eur. J. Immunol. 31(1), 94-106). Major drawbacks of this therapy are T cell activation manifested in cytokine release due to cross-linking between T cells and Fc γ R-bearing cells and the human anti-mouse antibody (HAMA) response. Several publications have described alterations such as humanization of OKT3 to reduce these side effects: US 5,929,212; US 5,885,573 and others. On the other hand, OKT3 or other anti-CD3-antibodies can be used as immunopotentiating agents to stimulate T cell activation and proliferation (US 6,406,696 Bluestone; US 6,143,297 Bluestone; US 6,113,901 Bluestone; Yannelli 1990, J. Immunol. Meth. 1, 91-100). Anti-CD3-antibodies have also been described as agents used in combination with anti-CD28-antibodies to induce T cell proliferation (US 6,352,694). OKT3 has further been used by itself or as a component of a bispecific antibody to target cytotoxic T cells to tumor cells or virus infected cells (Nitta 1990, Lancet 335, 368-376; Sanna 1995, Bio/Technology 13, 1221-1224; WO 99/54440).

) Approaches up to now using antibodies as agents for recruiting T-cells have been hampered by several findings. First, natural or engineered antibodies having a high binding affinity to T-cells often do not activate the T-cells to which they are bound.

Second, natural or engineered antibodies having a low binding affinity to T-cells are also often ineffective with respect to their ability to trigger T-cell mediated cell lysis.

Bispecific antibodies comprising specificities for human CD19 and human CD3 which are not of the single-chain format and which retarget T-cell cytotoxicity to lymphoma cells in an MHC-independent manner have already been shown to be effective in vivo in animal models (Bohlen, Cancer Res 57 (1997), 1704-9; Demanet, Int J Cancer Suppl 7 (1992), 67-8) as well as in some pilot clinical trials. So far these antibodies were constructed by hybrid-hybridoma techniques, by covalently linking the monoclonal antibodies (Anderson, Blood 80 (1992), 2826-34) or by a diabody approach (Kipriyanov, Int. J. Cancer 77 (1998), 763-772). More extensive clinical studies have been hampered by the fact that these antibodies have low biological activity such that high dosages have to be administered and that application of the antibodies alone did not provide for a beneficial therapeutic effect. Furthermore, the availability of clinical grade material was limited. The prior art has exemplified bispecific single chain antibodies comprising specificities for both human CD3 and human CD19 antigens (Loffler, Blood 95 (2000), 2098-103; WO 99/54440; Dreier, Int. J. Cancer. 100 (2002), 690-7). WO 99/54440 documents the successful clinical use of a construct in the format $V_L(CD19)-V_H(CD19)-V_H(CD3)-V_L(CD3)$ and stresses that the order of variable domains within the construct is not decisive.

Yet, in particular for distinct clinical and pharmaceutical uses, constructs have to be provided which can be produced in large amounts by reasonably high levels of expression of the recombinant constructs and by adequate purification methods after expression. In the event that extremely low amounts of pure protein are obtained, it becomes prohibitively cumbersome and/or costly to generate therapeutically relevant amounts of such constructs. In the special case of proteinaceous medicaments intended for parental administration, these medicaments should be highly active and potent, even in low concentrations, in order to avoid adverse side-effects due to excessive protein concentrations or voluminous infusion/injection solutions. Disadvantages of highly-dosed proteinaceous medicaments or highly-dosed medicaments based on nucleic acids comprise, inter alia, the promotion of hypersensitivities and inflammatory events, in particular at the site of administration.

- Thus, the technical problem of the present invention is the provision of means and methods for the generation of well tolerated and convenient medicaments for the treatment and or amelioration of B-cell related or B-cell mediated disorders.
- 5 Accordingly, the present invention relates to a pharmaceutical composition comprising a bispecific single chain antibody construct, said bispecific single chain antibody construct comprising binding domains specific for human CD3 and human CD19, wherein the corresponding variable heavy chain regions (V_H) and the corresponding variable light chain regions (V_L) are arranged, from N-terminus to C-
0 terminus, in the order,

$V_H(CD19)-V_L(CD19)-V_H(CD3)-V_L(CD3),$
 $V_H(CD3)-V_L(CD3)-V_H(CD19)-V_L(CD19)$ or
 $V_H(CD3)-V_L(CD3)-V_L(CD19)-V_H(CD19).$

- 5 Accordingly, " V_L " and " V_H " means the variable domain of the light and heavy chain of specific anti-CD19 (CD19) and anti-CD3 (CD3) antibodies.

In accordance with this invention, the term "pharmaceutical composition" relates to a composition for administration to a patient, preferably a human patient. In a preferred embodiment, the pharmaceutical composition comprises a composition for parenteral, transdermal, intraluminal, intraarterial, intrathecal administration or by direct injection into tissue. It is in particular envisaged that said pharmaceutical composition is administered to a patient via infusion or injection. Administration of the suitable compositions may be effected by different ways, e.g., by intravenous, 0 intraperitoneal, subcutaneous, intramuscular, topical or intradermal administration. The pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier. Examples of suitable pharmaceutical carriers are well known in the art and include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile 5 solutions, etc. Compositions comprising such carriers can be formulated by well known conventional methods. These pharmaceutical compositions can be administered to the subject at a suitable dose. The dosage regimen will be determined by the attending physician and clinical factors. As is well known in the 0 medical arts, dosages for any one patient depend upon many factors, including the
medical arts, dosages for any one patient depend upon many factors, including the

patient's size, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently. A preferred dosage for administration might be in the range of 0.24 µg to 48 mg, preferably 0.24 µg to 24 mg, more preferably 0.24 µg to 2.4 mg, even more preferably 0.24 µg to 1.2 mg and most preferably 0.24 µg to 240 µg units per kilogram of body weight per day. Particularly preferred dosages are recited herein below. Progress can be monitored by periodic assessment. Dosages will vary but a preferred dosage for intravenous administration of DNA is from approximately 10^6 to 10^{12} copies of the nucleic acid molecule, preferably a DNA molecule. The pharmaceutical compositions of the invention comprising proteinaceous or nucleic acid compounds described herein may be administered locally or systematically. Administration will generally be parenterally, e.g., intravenously; DNA may also be administered directed to the target site, e.g., by biolistic delivery to an internal or external target site or by catheter to a site in an artery. Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, inert gases and the like. In addition, the pharmaceutical composition of the present invention might comprise proteinaceous carriers, like, e.g., serum albumin or immunoglobulin, preferably of human origin. It is envisaged that the pharmaceutical composition of the invention might comprise, in addition to the proteinaceous bispecific single chain antibody constructs or nucleic acid molecules or vectors encoding the same (as described in this invention), further biologically active agents, depending on the intended use of the pharmaceutical composition. Such agents might be drugs acting on the gastro-intestinal system, drugs acting as cytostatica, drugs preventing hyperurikemia, drugs inhibiting immunoreactions (e.g.

corticosteroids), drugs acting on the circulatory system and/or agents such as T-cell co-stimulatory molecules or cytokines known in the art.

The term "bispecific single chain antibody construct" relates to a construct comprising one domain consisting of variable regions (or parts thereof) as defined above, capable of specifically interacting with/binding to human CD3 and comprising a second domain consisting of variable regions (or parts thereof) as defined above, capable of specifically interacting with/binding to human CD19.

Said binding/interaction is also understood to define a "specific recognition". The term "specifically recognizing" means in accordance with this invention that the antibody molecule is capable of specifically interacting with and/or binding to at least two amino acids of each of the human target molecule as defined herein. Said term relates to the specificity of the antibody molecule, i.e. to its ability to discriminate between the specific regions of the human target molecule as defined herein. The specific interaction of the antigen-interaction-site with its specific antigen may result in an initiation of a signal, e.g. due to the induction of a change of the conformation of the antigen, an oligomerization of the antigen, etc. Further, said binding may be exemplified by the specificity of a "key-lock-principle". Thus, specific motifs in the amino acid sequence of the antigen-interaction-site and the antigen bind to each other as a result of their primary, secondary or tertiary structure as well as the result of secondary modifications of said structure. The specific interaction of the antigen-interaction-site with its specific antigen may result as well in a simple binding of said site to the antigen.

The term "specific interaction" as used in accordance with the present invention means that the bispecific single chain construct does not or essentially does not cross-react with (poly)peptides of similar structures. Cross-reactivity of a panel of bispecific single chain construct under investigation may be tested, for example, by assessing binding of said panel of bispecific single chain construct under conventional conditions (see, e.g., Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, 1988 and *Using Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, 1999) to the (poly)peptide of interest as well as to a number of more or less (structurally and/or functionally) closely related (poly)peptides. Only those antibodies that bind to the (poly)peptide/protein of interest but do not or do not essentially bind to any of the other (poly)peptides are considered specific for the (poly)peptide/protein of interest.

Examples for the specific interaction of an antigen-interaction-site with a specific antigen comprise the specificity of a ligand for its receptor. Said definition particularly comprises the interaction of ligands which induce a signal upon binding to its specific receptor. Examples for corresponding ligands comprise cytokines which interact/bind with/to its specific cytokine-receptors. Also particularly comprised by said definition is the binding of an antigen-interaction-site to antigens like antigens of the selectin family, integrins and of the family of growth factors like EGF. An other example for said interaction, which is also particularly comprised by said definition, is the interaction of an antigenic determinant (epitope) with the antigenic binding site of an antibody.

The term "binding to/interacting with" may also relate to a conformational epitope, a structural epitope or a discontinuous epitope consisting of two regions of the human target molecules or parts thereof. In context of this invention, a conformational epitope is defined by two or more discrete amino acid sequences separated in the primary sequence which come together on the surface of the molecule when the polypeptide folds to the native protein (Sela, (1969) Science 166, 1365 and Laver, (1990) Cell 61, 553-6).

The term "discontinuous epitope" means in context of the invention non-linear epitopes that are assembled from residues from distant portions of the polypeptide chain. These residues come together on the surface of the molecule when the polypeptide chain folds into a three-dimensional structure to constitute a conformational/structural epitope.

According to the present invention the term "variable region" used in the context with Ig-derived antigen-interaction comprises fragments and derivatives of (poly)peptides which at least comprise one CDR derived from an antibody, antibody fragment or derivative thereof. It is envisaged by the invention, that said at least one CDR is preferably a CDR3, more preferably the CDR3 of the heavy chain of an antibody (CDR-H3). However, other antibody derived CDRs are also particularly comprised by the term "variable region".

The "specific binding" of an antibody is characterized primarily by two parameters: a qualitative parameter (the binding epitope, or where the antibody binds) and a quantitative parameter (the binding affinity, or how strongly it binds where it does). Which epitope is bound by an antibody can advantageously be determined by e.g. known FACS methodology, peptide-spot epitope mapping, mass spectroscopy. The

strength of antibody binding to a particular epitope may be advantageously be determined by e.g. known BIACore and/or ELISA methodologies. A combination of such techniques allows the calculation of a signal:noise ratio as a representative measure of binding specificity. In such a signal:noise ratio, the signal represents the strength of antibody binding to the epitope of interest, whereas the noise represents the strength of antibody binding to other, non-related epitopes differing from the epitope of interest. In general, any time an antibody binds more frequently and/or strongly to one epitope than another epitope, such antibody may be said to bind the former epitope specifically. Preferably, a signal:noise ratio for an epitope of interest which is about 50-fold higher than for other epitopes different from the epitope of interest may be taken as an indication that the antibody evaluated binds the epitope of interest in a specific manner, i.e. is a "specific binder".

As will be detailed below, a part of a variable region may be at least one CDR ("Complementary determining region"), most preferably at least the CDR3 region.

Said two domains/regions in the single chain antibody construct are preferably covalently connected to one another as a single chain. This connection can be effected either directly (domain1 directed against CD3 – domain2 directed against CD 19 or domain1 directed against CD19 – domain2 directed against CD3) or through an additional polypeptide linker sequence (domain1 – linker sequence – domain2). In the event that a linker is used, this linker is preferably of a length and sequence sufficient to ensure that each of the first and second domains can, independently from one another, retain their differential binding specificities. Most preferably and as documented in the appended examples, the "bispecific single chain antibody construct" to be employed in the pharmaceutical composition of the invention is a bispecific single chain Fv (scFv). Bispecific single chain molecules are known in the art and are described in WO 99/54440, Mack, J. Immunol. (1997), 158, 3965-3970, Mack, PNAS, (1995), 92, 7021-7025, Kufer, Cancer Immunol. Immunother., (1997), 45, 193-197, Löffler, Blood, (2000), 95, 6, 2098-2103, Brühl, Immunol., (2001), 166, 2420-2426, Kipriyanov, J. Mol. Biol., (1999), 293, 41-56.

The term "single-chain" as used in accordance with the present invention means that said first and second domain of the bispecific single chain construct are covalently linked, preferably in the form of a co-linear amino acid sequence encodable by a single nucleic acid molecule.

As pointed out above, CD19 denotes an antigen that is expressed in the B lineage such as in the pro B cell and the mature B cell, it is not shed, is uniformly expressed on all lymphoma cells, and is absent from stem cells (Haagen (1992) loc.cit; Uckun (1988) PNAS 85, 8603-8607). CD3 denotes an antigen that is expressed on T-cells as part of the multimolecular T-cell receptor complex and that consists of at least three different chains CD3 ϵ , CD3 δ and CD3 γ . Clustering of CD3 on T-cells, e.g., by immobilized anti-CD3-antibodies, leads to T-cell activation similar to the engagement of the T-cell receptor but independent from its clone typical specificity. Actually, most anti-CD3-antibodies recognize the CD3 ϵ -chain.

-) Antibodies that specifically recognize CD19 or CD3 antigen are described in the prior art, e.g., in Dubel (1994), J. Immunol. Methods 175, 89-95; Traunecker (1991) EMBO J. 10, 3655-3699 or Kipriyanov, (1998), loc.cit. Further illustrative examples are listed below. Furthermore, antibodies directed against human CD3 and/or human CD19 can be generated by conventional methods known in the art.

Here it was surprisingly found that bispecific single chain constructs directed against human CD3 and human CD19 and comprising variable regions (VH (corresponds to V_H), VL (corresponds to V_L)) or parts thereof (e.g. CDRs) in the format V_H(CD19)-V_L(CD19)-V_H(CD3)-V_L(CD3), V_H(CD3)-V_L(CD3)-V_H(CD19)-V_L(CD19) or V_H(CD3)-V_L(CD3)-V_L(CD19)-V_H(CD19) are particularly useful as pharmaceutical compositions since these constructs are advantageous over constructs of similar formats, like V_L(CD3)-V_H(CD3)-V_L(CD19)-V_H(CD19), V_L(CD3)-V_H(CD3)-V_H(CD19)-V_L(CD19), V_L(CD19)-V_H(CD19)-V_L(CD3)-V_H(CD3) or V_H(CD19)-V_L(CD19)-V_L(CD3)-V_H(CD3). The latter four constructs/construct formats are characterized by less advantageous cytotoxic activity as reflected by EC₅₀ values and/or less efficient or complete purifications as shown in the appended examples. It was in particular surprising that the anti-CD3 part of the single chain constructs to be employed in accordance with the invention are highly bioactive in N- as well as C-terminal position, whereas arrangements in V_H(CD3)-V_L(CD3) are particularly preferred. The constructs to be employed in the pharmaceutical composition of the invention are characterized by advantageous production and purification properties as well as by their high bioactivity, i.e. their desired cytotoxic activity. The corresponding high bioactivity is reflected by low to very low EC₅₀ values as determined in cytotoxicity tests. The term "EC₅₀" corresponds, in context of this invention, to EC₅₀ values as determined

according to the methods known in the art and as illustrated in the appended examples: a standard dose-response curve is defined by four parameters: the baseline response (Bottom), the maximum response (Top), the slope of dose-response increase, and the drug concentration that elicits a response halfway between baseline and maximum (EC_{50}). EC_{50} is defined as the concentration of a drug or molecule that elicits a response half way between the baseline (Bottom) and maximum response (Top). The percentage of cell lysis (i.e. cytotoxic activity) may be determined by, inter alia, release assays disclosed herein above, for example, ^{51}Cr release assays, LDH-release assays, calcein release assays and the like. Most preferably, in the context of this invention fluorochrome release assays are employed as illustrated in the appended examples. Here, strong cytotoxic activity against CD19-positive cells (experimentally for example NALM6 cells) of the bispecific single chain constructs described herein relates to a molecule comprising EC_{50} values </-(less or equal to) 500 pg/ml, more preferably </-400 pg/ml, even more preferably </-300 pg/ml, even more preferably </-250 pg/ml, most preferably </-200 pg/ml. Here, it was surprisingly found that certain constructs having the formats VH(CD19)-VL(CD19)-VH(CD3)-VL(CD3) and VH(CD3)-VL(CD3)-VH(CD19)-VL(CD19) demonstrate advantageous properties in addition to high cytotoxic activity which make these constructs well-suited to inclusion in pharmaceutical compositions. In contrast, other constructs such as VH(CD19)-VL(CD19)-VL(CD3)-VH(CD3) are only very poorly producible/isolatable making, for example the latter construct very poorly suited to inclusion in pharmaceutical compositions.

In a preferred embodiment of the pharmaceutical composition of this invention, the VH and VL regions of said CD3 specific domain are derived from a CD3 specific antibody selected from the group consisting of X35-3, VIT3, BMA030 (BW264/56), CLB-T3/3, CRIS7, YTH12.5, F111-409, CLB-T3.4.2, WT31, WT32, SPv-T3b, 11D8, XIII-141, XIII-46, XIII-87, 12F6, T3/RW2-8C8, T3/RW2-4B6, OKT3D, M-T301, SMC2 and F101.01. These CD3-specific antibodies are well known in the art and, inter alia, described in Tunnacliffe (1989), Int. Immunol. 1, 546-550. In a more preferred embodiment, said VH and VL regions of said CD3 specific domain are derived from OKT-3 (as defined and described above) or TR-66. Even more preferred (and as illustrated in the appended examples) said VH and VL regions are or are derived from an antibody/antibody derivative specifically directed against CD3 described by

Traunecker (1991), EMBO J. 10, 3655-3659. In accordance with this invention, said VH and VL regions are derived from antibodies/antibody derivatives and the like which are capable of specifically recognizing human CD3 epsilon in the context of other TCR subunits, e.g. in mouse T cells transgenic for human CD3 epsilon. These transgenic mouse cells express human CD3 epsilon in a native or near native conformation. Accordingly, the VH and VL regions derived from a CD3-epsilon-specific antibody are most preferred in accordance with this invention and said (parental) antibodies should be capable of specifically binding epitopes reflecting the native or near native structure or a conformational epitope of human CD3 presented in context of the TCR complex. Such antibodies have been classified by Tunnacliffe (1989) as "group II" antibodies. Further classifications in Tunnacliffe (1989) comprise the definition of "group I" and "group III" antibodies directed against CD3. "Group I" antibodies, like UCHT1, recognize CD3 epsilon both expressed as recombinant protein as well as part of the TCR on the cell surface. Therefore, "group I" antibodies are highly specific for CD3 epsilon. In contrast, the herein preferred "group II" antibodies recognize CD3 epsilon only in the native TCR complex in association with other TCR subunits. Without being bound by theory, it is speculated in context of this invention that in "group II" antibodies, the TCR context is required for recognition of CD3 epsilon. CD3 gamma and/or delta, being associated with epsilon, are also involved in binding of "group II" antibodies. All three subunits express immuno-tyrosine activation motifs (ITAMs) which can be tyrosine phosphorylated by protein tyrosine kinases. For this reason "group II" antibodies induce T cell signaling via CD3 epsilon, gamma and delta, leading to a stronger signal compared to "group I" antibodies selectively inducing T cell signaling via CD3 epsilon. Yet, since for therapeutic applications induction of a strong T cell signaling is desired, the VH (CD3) /VL (CD3)- regions (or parts thereof) to be employed in the bispecific single chain constructs comprised in the inventive pharmaceutical composition, are preferably derived from antibodies directed against human CD3 and classified as "group II" by Tunnacliffe (1989), loc.cit..

Antibodies/antibody molecules/antibody derivatives directed against human CD19 which provide for variable regions (V_H and V_L) to be employed in the bispecific single chain construct(s) comprised in the inventive pharmaceutical composition are also well known in the art and illustrated in the appended examples. Preferred antibodies directed to human CD19 are: 4G7 (Meecker (1984) Hybridoma 3, 305-20); B4

(Freedman (1987) Blood 70, 418-27; B43 (Bejcek (1995) Cancer Res. 55, 2346-51); BU12 (Flavell (1995) Br. J. Cancer 72, 1373-9); CLB-CD19 (De Rie (1989) Cell. Immunol. 118, 368-81); Leu-12 (MacKenzie (1987), J. Immunol. 139, 24-8); SJ25-C1 (GenTrak, Plymouth Meeting, Pa)

In a most preferred embodiment of the invention said V_H (CD19) and V_L (CD19) regions (or parts, like CDRs, thereof) are derived from the antibody provided by the HD37 hybridoma (Pezzutto (1997), J. Immunol. 138, 2793-9).

-) As is well known, Fv, the minimum antibody fragment which contains a complete antigen recognition and binding site, consists of a dimer of one heavy and one light chain variable domain (V_H and V_L) in non-covalent association. In this configuration corresponding to the one found in native antibodies, the three CDRs of each variable domain interact to define an antigen binding site on the surface of the V_H - V_L dimer.
-) Collectively, the six CDRs confer antigen binding specificity to the antibody. Frameworks (FRs) flanking the CDRs have a tertiary structure which is essentially conserved in native immunoglobulins of species as diverse as human and mouse. These FRs serve to hold the CDRs in their appropriate orientation. The constant domains are not required for binding function, but may aid in stabilizing V_H - V_L interaction.

It is also envisaged in context of the present invention that the bispecific antibody constructs provided in the pharmaceutical composition of the invention are further modified. In particular, it is envisaged that the bispecific single chain antibody construct in the format V_H (CD19)- V_L (CD19)- V_H (CD3)- V_L (CD3), V_H (CD3)- V_L (CD3)- V_H (CD19)- V_L (CD19) or V_H (CD3)- V_L (CD3)- V_L (CD19)- V_H (CD19) as defined herein are deimmunized. Most preferably, at least the CD3-binding portion is deimmunized. Deimmunization entails carrying out substitutions of amino acids within potential T cell epitopes.

) It is envisaged and preferred that the pharmaceutical composition of the invention, comprises a bispecific single chain antibody construct in the format V_H (CD19)- V_L (CD19)- V_H (CD3)- V_L (CD3), V_H (CD3)- V_L (CD3)- V_H (CD19)- V_L (CD19) or V_H (CD3)- V_L (CD3)- V_L (CD19)- V_H (CD19) as defined above, wherein said V_H region comprises at

least one CDR3 region (CDR-H3 or CDR-3 of V_H) comprising the amino acid sequence: SEQ ID NO. 54 or 77.

The term "CDR-region" as used herein denotes the "complementary determining region" of an antibody molecule. Accordingly, the term "CDR-3 region", synonymous with the term "CDR3 region", relates to the "complementary determining region 3" of an antibody molecule/antibody construct. The same applies, mutatis mutandis, for corresponding CDR-2 and CDR-1 regions. It is envisaged and preferred that the bispecific single chain construct comprised in the pharmaceutical composition of the present invention does not only comprise CDR-3 regions, but also comprises CDR-1

or CDR-2 region(s) of variable regions/variable domains (VH/VL) of antibodies/antibody molecules directed against human CD3 and human CD19. Most preferably, the said molecule comprises at least one CDR-3 region of a VH and at least one CDR-3 region of an VL-domain of an antibody directed against CD3 as well as at least one CDR-3 region of an VH and at least one CDR-3 region of a VL-domain of an antibody directed against CD19. Most preferably, the bispecific single chain construct of the inventive pharmaceutical composition comprises in addition at least one further CDR-1 region and/or at least one further CDR-2 region in the VH and VL domains defined herein. Accordingly, the bispecific single chain construct defined herein may comprise CDR-1, CDR-2, CDR-3 region of VL as well as CDR-1, CDR-2, CDR-3 region of VH of an antibody/antibody molecule directed against human CD3, preferably human CD3 epsilon, and comprises, in addition, CDR-1, CDR-2, CDR-3 region of VL as well as CDR-1, CDR-2, CDR-3 region of VH of an antibody/antibody molecule directed against human CD19.

Preferably, said VH (CD3) region comprises at least one CDR2 region comprising the amino acid sequence: SEQ ID NO. 53 or 76. It is also envisaged that said VH (CD3) region comprises at least one CDR1 region comprising the amino acid sequence: SEQ ID NO. 52 or 75.

The VL (CD3) region comprises, preferably, at least one CDR3 region comprising the amino acid sequence: SEQ ID NO. 57 or 74. The VL (CD3) may comprise at least one CDR2 region comprising the amino acid sequence: SEQ ID NO. 56 or 73. The VL (CD3) may also comprise at least one CDR1 region comprising the amino acid sequence: SEQ ID NO. 55 or 72.

As mentioned herein above, the constructs comprised in the inventive pharmaceutical composition comprise at least one CDR-3 of a VH-region of an antibody directed against human CD3, at least one CDR-3 of a VL-region of an antibody directed against human CD3, at least one CDR-3 of a VH-region of an antibody directed against human CD19 and at least one CDR-3 of a VL-region of an antibody directed against human CD19. However, in a most preferred embodiment and as illustrated in the appended examples, the bispecific single chain constructs comprised in the inventive pharmaceutical composition comprise VH and VL regions which comprise not only CDR-3 but also CDR1 and/or CDR2 regions. In particular, CDR-regions, preferably CDR1 regions, more preferably CDR1 regions and CDR2 regions, most preferably CDR1 regions, CDR2 regions and CDR3 regions as defined herein may be employed to generate further bispecific single chain constructs defined herein. Most preferably the bispecific single chain constructs comprised in the inventive pharmaceutical composition are derived from the parental antibodies as disclosed herein and share, as disclosed above, the CDR-3 domain of the VH-region and the CDR-3 domain of the VL-region with said parental antibodies. Yet, it is also envisaged that the bispecific single chain constructs comprised in the inventive pharmaceutical composition also comprises modified CDR regions. It is, e.g. envisaged that in particular CDR2 and/or CDR1 regions (or frameworks or linkers between CDRs) are deimmunized.

In a preferred embodiment of the invention the bispecific single chain antibody construct comprised in the inventive pharmaceutical composition comprises an amino acid sequence selected from the group consisting of (a) an amino acid sequence as depicted in SEQ ID NOs 2, 10 or 14; (b) an amino acid sequence encoded by a nucleic acid sequence as shown in SEQ ID NOs 1, 9 or 13; (c) an amino acid sequence encoded by a nucleic acid sequence hybridizing under stringent conditions to the complementary nucleic acid sequence of (b); and (d) an amino acid sequence encoded by a nucleic acid sequence which is degenerate as a result of the genetic code to a nucleotide sequence of (b).

The term "hybridizing" as used herein refers to polynucleotides/nucleic acid sequences which are capable of hybridizing to the polynucleotides encoding bispecific single chain constructs as defined herein or parts thereof. Therefore, said

polynucleotides may be useful as probes in Northern or Southern Blot analysis of RNA or DNA preparations, respectively, or can be used as oligonucleotide primers in PCR analysis dependent on their respective size. Preferably, said hybridizing polynucleotides comprise at least 10, more preferably at least 15 nucleotides in length while a hybridizing polynucleotide of the present invention to be used as a probe preferably comprises at least 100, more preferably at least 200, or most preferably at least 500 nucleotides in length.

It is well known in the art how to perform hybridization experiments with nucleic acid molecules, i.e. the person skilled in the art knows what hybridization conditions s/he has to use in accordance with the present invention. Such hybridization conditions are referred to in standard text books such as Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory (2001) N.Y. Preferred in accordance with the present inventions are polynucleotides which are capable of hybridizing to the polynucleotides of the invention or parts thereof, under stringent hybridization conditions.

"Stringent hybridization conditions" refer, i.e. to an overnight incubation at 42°C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1 x SSC at about 65°C. Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37°C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M NaH₂po₄; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 µg/ml salmon sperm blocking DNA; followed by washes at 50°C with 1 X SSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC). It is of note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTTO, heparin, denatured salmon sperm DNA, and commercially available

proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

As mentioned above, the said variable domains comprised in the herein described bispecific single chain constructs are connected by additional linker sequences. The term "peptide linker" defines in accordance with the present invention an amino acid sequence by which the amino acid sequences of the first domain and the second domain of the monomer of the trimeric polypeptide construct of the invention are linked with each other. An essential technical feature of such peptide linker is that said peptide linker does not comprise any polymerization activity. A particularly preferred peptide linker is characterized by the amino acid sequence Gly-Gly-Gly-Gly-Ser, i.e. Gly₄Ser, or polymers thereof, i.e. (Gly₄Ser)_x, where x is an integer 1 or greater. The characteristics of said peptide linker, which comprise the absence of the promotion of secondary structures are known in the art and described e.g. in Dall'Acqua et al. (Biochem. (1998) 37, 9266-9273), Cheadle et al. (Mol Immunol (1992) 29, 21-30) and Raag and Whitlow (FASEB (1995) 9(1), 73-80). Also particularly preferred are peptide linkers which comprise fewer amino acid residues. An envisaged peptide linker with less than 5 amino acids comprises 4, 3, 2 or one amino acid(s) wherein Gly-rich linkers are preferred. A particularly preferred "single" amino acid in context of said "peptide linker" is Gly. Accordingly, said peptide linker may consist of the single amino acid Gly. Furthermore, peptide linkers which also do not promote any secondary structures are preferred. The linkage of said domains to each other can be provided by, e.g. genetic engineering, as described in the examples. Methods for preparing fused and operatively linked bispecific single chain constructs and expressing them in mammalian cells or bacteria are well-known in the art (e.g. WO 99/54440 or Sambrook et al., Molecular Cloning: A Laboratory Manual; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2001).

The present invention also provides for a pharmaceutical composition comprising a nucleic acid sequence encoding a bispecific single chain antibody construct as defined above, i.e. a bispecific construct in the format VH(CD19)-VL(CD19)-VH(CD3)-VL(CD3), VH(CD3)-VL(CD3)-VH(CD19)-VL(CD19) or VH(CD3)-VL(CD3)-VL(CD19)-VH(CD19). Of these, nucleic acid sequences encoding bispecific constructs of the formats VH(CD19)-VL(CD19)-VH(CD3)-VL(CD3) and VH(CD3)-

VL(CD3)-VH(CD19)-VL(CD19) are each especially advantageous for inclusion in such pharmaceutical compositions. In contrast, a nucleic acid sequence encoding a bispecific construct of, for example, the format VH(CD19)-VL(CD19)-VL(CD3)-VH(CD3) is very poorly suited for inclusion in pharmaceutical compositions, the latter being very poorly producible/isolatable.

Said nucleic acid molecule may be a naturally occurring nucleic acid molecule as well as a recombinant nucleic acid molecule. The nucleic acid molecule of the invention may, therefore, be of natural origin, synthetic or semi-synthetic. It may comprise DNA, RNA as well as PNA and it may be a hybrid thereof.

It is evident to the person skilled in the art that regulatory sequences may be added to the nucleic acid molecule of the invention. For example, promoters, transcriptional enhancers and/or sequences which allow for induced expression of the polynucleotide of the invention may be employed. A suitable inducible system is for example tetracycline-regulated gene expression as described, e.g., by Gossen and Bujard (Proc. Natl. Acad. Sci. USA 89 (1992), 5547-5551) and Gossen et al. (Trends Biotech. 12 (1994), 58-62), or a dexamethasone-inducible gene expression system as described, e.g. by Crook (1989) EMBO J. 8, 513-519.

Furthermore, it is envisaged for further purposes that nucleic acid molecules may contain, for example, thioester bonds and/or nucleotide analogues. Said modifications may be useful for the stabilization of the nucleic acid molecule against endo- and/or exonucleases in the cell. Said nucleic acid molecules may be transcribed by an appropriate vector containing a chimeric gene which allows for the transcription of said nucleic acid molecule in the cell. In this respect, it is also to be understood that the polynucleotide of the invention can be used for "gene targeting" or "gene therapeutic" approaches. In another embodiment said nucleic acid molecules are labeled. Methods for the detection of nucleic acids are well known in the art, e.g., Southern and Northern blotting, PCR or primer extension. This embodiment may be useful for screening methods for verifying successful introduction of the nucleic acid molecules described above during gene therapy approaches.

Said nucleic acid molecule(s) may be a recombinantly produced chimeric nucleic acid molecule comprising any of the aforementioned nucleic acid molecules either alone or in combination. Preferably, the nucleic acid molecule is part of a vector.

5 The present invention therefore also relates to a pharmaceutical composition comprising a vector comprising the nucleic acid molecule described in the present invention.

The vector of the present invention may be, e.g., a plasmid, cosmid, virus,
1 bacteriophage or another vector used e.g. conventionally in genetic engineering, and
may comprise further genes such as marker genes which allow for the selection of
said vector in a suitable host cell and under suitable conditions. Q

Furthermore, the vector to be employed in the generation of the bispecific single
5 chain constructs described herein or to be employed in a pharmaceutical composition
of the present invention may, in addition to the nucleic acid sequences of the
invention, comprise expression control elements, allowing proper expression of the
coding regions in suitable hosts. Such control elements are known to the artisan and
may include a promoter, a splice cassette, translation initiation codon, translation and
1 insertion site for introducing an insert into the vector. Preferably, said nucleic acid
molecule is operatively linked to said expression control sequences allowing
expression in eukaryotic or prokaryotic cells.

Control elements ensuring expression in eukaryotic and prokaryotic cells are well
known to those skilled in the art. As mentioned herein above, they usually comprise
5 regulatory sequences ensuring initiation of transcription and optionally poly-A signals
ensuring termination of transcription and stabilization of the transcript. Additional
regulatory elements may include transcriptional as well as translational enhancers,
and/or naturally-associated or heterologous promoter regions. Possible regulatory
elements permitting expression in for example mammalian host cells comprise the
1 CMV- HSV thymidine kinase promoter, SV40, RSV-promoter (Rous Sarcoma Virus),
human elongation factor 1 α -promoter, the glucocorticoid-inducible MMTV-promoter
(Moloney Mouse Tumor Virus), metallothionein- or tetracyclin-inducible promoters, or
enhancers, like CMV enhancer or SV40-enhancer. For expression in white blood
cells, it is envisaged that specific promoters can be employed. Said promoters are

known in the art and, inter alia, described or mentioned in Hendon (2002), Clin. Immunol. 103, 145-153; Chinnosamy (2000) Blood 96, 1309-1316; Zhang (2003) J. Acq. Immun. Def. Synd. 245-254; Kaiser (2003) Science 299, 495; Hacein-Bay (2002) Int. J. Hemat. 76, 295-298; Hacein-Bay (2002) New Eng. J. Med. 346, 1185-1193; Ainti (2002) Science 296, 2410-2413. For the expression in prokaryotic cells, a multitude of promoters including, for example, the tac-lac-promoter or the trp promoter, has been described. Besides elements which are responsible for the initiation of transcription such regulatory elements may also comprise transcription-termination signals, such as SV40-poly-A site or the tk-poly-A site, downstream of the polynucleotide. In this context, suitable expression vectors are known in the art such as Okayama-Berg cDNA expression vector pcDV1 (Pharmacia), pRc/CMV, pcDNA1, pcDNA3 (In-vitogene), pSPORT1 (GIBCO BRL), pX (Pagano (1992) Science 255, 1144-1147), yeast two-hybrid vectors, such as pEG202 and dpJG4-5 (Gyuris (1995) Cell 75, 791-803), or prokaryotic expression vectors, such as lambda gt11 or pGEX (Amersham-Pharmacia). Beside the nucleic acid molecules coding for the bispecific single chain constructs described herein, the vector may further comprise nucleic acid sequences encoding for secretion signals. Such sequences are well known to the person skilled in the art. Furthermore, depending on the expression system used, leader sequences capable of directing the peptides of the invention to a cellular compartment may be added to the coding sequence of the nucleic acid molecules of the invention and are well known in the art. The leader sequence(s) is (are) assembled in appropriate phase with translation, initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein, or a protein thereof, into the periplasmic space or extracellular medium. Optionally, the heterologous sequence can encode a fusion protein including an C- or N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product. Once the vector has been incorporated into the appropriate host, the host is maintained under conditions suitable for high level expression of the nucleotide sequences, and, as desired, the collection and purification of the bispecific single chain constructs described herein may follow. The invention also relates, accordingly, to hosts/host cells which comprise a vector as defined herein. Such hosts may be useful for in processes for obtaining bispecific single chain constructs comprised in the pharmaceutical composition of the invention as well as directly in

medical/pharmaceutical settings. Said host cells may also comprise transduced or transfected white blood cells, such as lymphocyte cells, preferably adult cells. Such host cells may be useful in transplantation therapies.

- ; Furthermore, the vector as well as the nucleic acid molecule described herein may be employed in gene therapy approaches. Gene therapy, which is based on introducing therapeutic genes into cells by ex-vivo or in-vivo techniques is one of the most important applications of gene transfer. Suitable vectors, methods or gene-delivering systems for in-vitro or in-vivo gene therapy are described in the literature) and are known to the person skilled in the art; see, e.g., Giordano, Nature Medicine 2 (1996), 534-539; Schaper, Circ. Res. 79 (1996), 911-919; Anderson, Science 256 (1992), 808-813; Isner, Lancet 348 (1996), 370-374; Muhlhauser, Circ. Res. 77 (1995), 1077-1086; Onodua, Blood 91 (1998), 30-36; Verzeletti, Hum. Gene Ther. 9 (1998), 2243-2251; Verma, Nature 389 (1997), 239-242; Anderson, Nature 392 (Supp. 1998), 25-30; Wang, Gene Therapy 4 (1997), 393-400; Wang, Nature Medicine 2 (1996), 714-716; WO 94/29469; WO 97/00957; US 5,580,859; US 5,589,466; US 4,394,448 or Schaper, Current Opinion in Biotechnology 7 (1996), 635-640, and references cited therein. In particular, said vectors and/or gene delivery systems are also described in gene therapy approaches in blood, lymphocytes, bone) marrow and corresponding stem cells; see, e.g. Hendon (2002), Clin. Immunol. 103, 145-153; Chinnosamy (2000) Blood 96, 1309-1316; Zhang (2003) J. Acq. Immun. Def. Synd. 245-254; Kaiser (2003) Science 299, 495; Hacein-Bay (2002) Int. J. Hemat. 76, 295-298; Hacein-Bay (2002) New Eng. J. Med. 346, 1185-1193; Ainti (2002) Science 296, 2410-2413. The nucleic acid molecules and vectors comprised 5 in the pharmaceutical composition of the invention may be designed for direct introduction or for introduction via liposomes, viral vectors (e.g. adenoviral, retroviral), electroporation, ballistic (e.g. gene gun) or other delivery systems into the cell. Additionally, a baculoviral system can be used as a eukaryotic expression system in insect cells for the nucleic acid molecules of the invention. The introduction and gene 0 therapeutic approach should, preferably, lead to the expression of a functional bispecific single chain construct as defined herein, whereby said expressed antibody molecule is particularly useful in the treatment, amelioration and/or prevention of B-cell related malignancies as defined herein. Preferably, the expression control sequences will be eukaryotic promoter systems in vectors capable of transforming of

transfected eukaryotic host cells, but control sequences for prokaryotic hosts may also be used. Once the vector has been incorporated into the appropriate host, the host is maintained under conditions suitable for high level expression of the nucleotide sequences, and as desired, the collection and purification of the bispecific single chain constructs may follow; see, e.g., the appended examples.

5

Therefore, in further embodiments of the invention, a pharmaceutical composition is provided which comprising a vector encoding a bispecific single chain construct in the format

0

$V_H(CD19)-V_L(CD19)-V_H(CD3)-V_L(CD3)$,
 $V_H(CD3)-V_L(CD3)-V_H(CD19)-V_L(CD19)$ or
 $V_H(CD3)-V_L(CD3)-V_L(CD19)-V_H(CD19)$

5

or a host transformed or transfected with said vector.

0

The pharmaceutical composition of the invention may also comprise a proteinaceous compound capable of providing an additional activation signal for immune effector cells. Such compounds may comprise, but are not limited to CD28 engagers, ICOS engagers, 41BB engagers, OX40 engagers, CD27 engagers, CD30 engagers, NKG2D engagers, IL2-R engagers or IL12-R engagers. In the light of the present invention, said "proteinaceous compounds" providing an activation signal for immune effector cells" may be, e.g. a further primary activation signal, or costimulatory (second) signal or any other accessory (third) activation signal. Examples are a TCR or TCR-like signal. Preferred formats of proteinaceous compounds comprise additional bispecific antibodies and fragments or derivatives thereof, e.g. bispecific scFv. Proteinaceous compounds can comprise, but are not limited to, scFv fragments specific for 4-1 BB, OX 40, CD27, CD70 or the receptors for B7-RP1, B7-H3 as well as scFv fragments specific for the T cell receptor or superantigens. Superantigens directly bind to certain subfamilies of T cell receptor variable regions in an MHC-independent manner thus mediating the primary T cell activation signal. The proteinaceous compound may also provide an activation signal for an immune effector cell which is a non-T cell. Examples for immune effector cells which are non-T cells comprise, inter alia, NK cells.

0

In a further embodiment of the present invention, a process for the production of a pharmaceutical composition of the invention is provided, said process comprises culturing a host defined above under conditions allowing the expression of the bispecific single chain antibody construct as defined herein and recovering the produced bispecific single chain antibody construct from the culture. The corresponding process is illustrated in the appended examples.

In a most preferred embodiment, the invention relates to the use of a bispecific single chain antibody construct, a nucleic acid sequence, a vector and/or a host as defined herein for the preparation of a pharmaceutical composition for the prevention, treatment or amelioration of a proliferative disease, a minimal residual cancer, a tumorous disease, an inflammatory disease, an immunological disorder, an autoimmune disease, an infectious disease, a viral disease, allergic reactions, parasitic reactions, graft-versus-host diseases, host-versus-graft diseases or B-cell malignancies, wherein said pharmaceutical composition optionally further comprises a proteinaceous compound capable of providing an activation signal for immune effector cells.

Accordingly, a method for the prevention, treatment or amelioration of a proliferative disease, a minimal residual cancer, a tumorous disease, an inflammatory disease, an immunological disorder, an autoimmune disease, an infectious disease, viral disease, allergic reactions, parasitic reactions, graft-versus-host diseases, host-versus-graft diseases, or B-cell malignancies is provided, whereby said method comprises the step of administering to a subject in need of such a prevention, treatment or amelioration a pharmaceutical composition of the invention. Most preferably said subject is a human.

The tumorous disease to be treated with the pharmaceutical composition of the invention may be a minimal residual cancer, for example, a minimal residual lymphoma or leukemia.

The autoimmune disease to be treated with the pharmaceutical composition of the invention may be an inflammatory autoimmune disease, for example, rheumatoid arthritis.

In accordance with this invention, it is also envisaged that a bispecific single chain antibody construct, a nucleic acid sequence, a vector and/or a host as described herein is/are used for the preparation of a pharmaceutical composition for depletion of B-cells.

The B cell malignancy to be treated with the pharmaceutical composition of the invention is in a most preferred embodiment non-Hodgkin lymphoma, B-cell leukemias or Hodgkin lymphoma. Accordingly, the present invention provides for a method for the treatment of B-cell malignancies, B-cell mediated autoimmune diseases or the depletion of B-cells and/or for a method delaying a pathological condition which is caused by B-cell disorders comprising administering the pharmaceutical composition of the invention into a mammal, preferably a human, affected by said malignancies, disease and/or pathological condition.

Finally, the invention provides for a kit comprising a bispecific single chain antibody construct, a nucleic acid sequence, a vector and/or a host as defined above. Said kit is particularly useful in the preparation of the pharmaceutical composition of the present invention and may, inter alia, consist of a container useful for injections or infusions. Advantageously, the kit of the present invention further comprises, optionally (a) buffer(s), storage solutions and/or remaining reagents or materials required for the conduct of medical or scientific purposes. Furthermore, parts of the kit of the invention can be packaged individually in vials or bottles or in combination in containers or multicontainer units. The kit of the present invention may be advantageously used, inter alia, for carrying out the method of the invention and could be employed in a variety of applications referred herein, e.g., as research tools or medical tools. The manufacture of the kits preferably follows standard procedures which are known to the person skilled in the art.

These and other embodiments are disclosed and encompassed by the description and Examples of the present invention. Further literature concerning any one of the antibodies, methods, uses and compounds to be employed in accordance with the present invention may be retrieved from public libraries and databases, using for example electronic devices. For example, the public database "Medline", available on

the Internet, may be utilized, for example under <http://www.ncbi.nlm.nih.gov/PubMed/medline.html>. Further databases and addresses, such as <http://www.ncbi.nlm.nih.gov/>, <http://www.infobiogen.fr/>, http://www.fmi.ch/biology/research_tools.html, <http://www.tigr.org/>, are known to the person skilled in the art and can also be obtained using, e.g., <http://www.lycos.com>.

5

The figures show:

Figure 1A: Schematic composition of VL/VH domain arrangements in anti-CD19 /

0 anti-CD3 single chain bispecific antibodies showing the binding sites of PCR primers.

A1, A2, B1 and B2 denote the positions, from the N-terminus to the C-terminus of the various V-regions used in constructing the anti-CD19 / anti-CD3 single chain bispecific antibodies.

5 Figure 1B: Schematic composition of VL/VH domain arrangements in anti-CD19 /

anti-CD3 single chain bispecific antibodies showing the recognition sites of restriction enzymes (L = Leader peptide). A1, A2, B1 and B2 denote the positions, from the N-terminus to the C-terminus of the various V-regions used in constructing the anti-CD19 / anti-CD3 single chain bispecific antibodies.

0

Figure 2: Bispecific single chain antibody elution pattern from a Zn-chelating Fractogel® column (IMAC) at 280 nm. The bottom line showing a first, minor step at

600 ml retention time and a second, major step at 700 ml indicates the theoretical gradient of elution buffer containing 0.5 M imidazole. High adsorption at 280 nm from

5 100-500 ml retention time was due to non-bound protein in the column flow through.

Protein from the elution peak at 670.05 ml retention time was used for further purification.

Figure 3: Bispecific single chain antibody elution pattern from a Sephadex S200

0 gel filtration column at 280 nm. The protein peak at 81.04 ml retention time

containing bispecific antibodies against CD3 and CD19 corresponds to a molecular weight of 52 kD. Fractions were collected from 50-110 ml retention time and were

indicated with black arrows numbered from 5-35.

Figure 4: Representative SDS-PAGE analysis of protein fractions of bispecific single chain antibodies. Lane M: Molecular weight marker Lane 1: cell culture supernatant; lane 2: IMAC flow-through; lane 3: IMAC eluate; lane 4: purified antibody against CD19 and CD3 obtained from gel filtration (Sephadex 200).

Figure 5: Representative western blot analysis of purified bispecific single chain antibody fractions. Western blot analysis of purified bispecific protein was performed with antibodies directed against the HisTag (PentaHis, Qiagen) and goat anti mouse Ig labelled with alkaline phosphatase. Lane 1: cell culture supernatant; lane 2: IMAC flow-through; lane 3: IMAC eluate; lane 4: purified antibody against CD19 and CD3 obtained from gel filtration (Sephadex 200).

Figure 6A: Binding data for the anti-CD19 (VL/VH) x anti-CD3 (VH/VL) construct as measured by FACS analysis on Nalm 6 (CD19+) and Jurkat (CD3+) cells. The left peak is the control; the right peak is the measurement of the fluorescence shift for the binding specificity of interest. A shift to the right indicates binding of the construct to CD19 or CD3, respectively. Arrangement of VH and VL domains is indicated from N to C terminus (N->C).

Figure 6B: Binding data for the anti-CD19 (VH/VL) x anti-CD3 (VH/VL) construct as measured by FACS analysis on Nalm 6 (CD19+) and Jurkat (CD3+) cells. The left peak is the control; the right peak is the measurement of the fluorescence shift for the binding specificity of interest. A shift to the right indicates binding of the construct to CD19 or CD3, respectively. Arrangement of VH and VL domains is indicated from N to C terminus (N->C).

Figure 6C: Binding data for the anti-CD19 (VL/VH) x anti-CD3 (VL/VH) construct as measured by FACS analysis on Nalm 6 (CD19+) and Jurkat (CD3+) cells. The left peak is the control; the right peak is the measurement of the fluorescence shift for the binding specificity of interest. A shift to the right indicates binding of the construct to CD19 or CD3, respectively. Arrangement of VH and VL domains is indicated from N to C terminus (N->C).

Figure 6D: Binding data for the anti-CD3 (VH/VL) x anti-CD19 (VH/VL) construct as measured by FACS analysis on Nalm 6 (CD19+) and Jurkat (CD3+) cells. The left peak is the control; the right peak is the measurement of the fluorescence shift for the binding specificity of interest. A shift to the right indicates binding of the construct to CD19 or CD3, respectively. Arrangement of VH and VL domains is indicated from N to C terminus (N->C).

Figure 6E: Binding data for the anti-CD3 (VL/VH) x anti-CD19 (VL/VH) construct as measured by FACS analysis on Nalm 6 (CD19+) and Jurkat (CD3+) cells. The left peak is the control; the right peak is the measurement of the fluorescence shift for the binding specificity of interest. A shift to the right indicates binding of the construct to CD19 or CD3, respectively. Arrangement of VH and VL domains is indicated from N to C terminus (N->C). ○

Figure 6F: Binding data for the anti-CD3 (VH/VL) x anti-CD19 (VL/VH) construct as measured by FACS analysis on Nalm 6 (CD19+) and Jurkat (CD3+) cells. The left peak is the control; the right peak is the measurement of the fluorescence shift for the binding specificity of interest. A shift to the right indicates binding of the construct to CD19 or CD3, respectively. Arrangement of VH and VL domains is indicated from N to C terminus (N->C). ○

Figure 7: Cytotoxicity data for selected domain-rearranged anti-CD3 / anti-CD19 constructs. CB15 T cell clone and NALM6 cells were used in an E:T ratio of 1:10. NALM6 target cells were labelled with calcein. Calcein release after cell lysis was determined by FACS analysis. ○

Figure 8: Binding of the 145-2C11 antibody to the recombinant, purified extracellular domain of the murine CD3 epsilon chain in ELISA. The ELISA was performed as described in Example 5, paragraph 1. The graph depicts absorption values for antigen preparation or an irrelevant antigen binding to the coated 145-2C11 antibody. Samples were done in 1:5, 1:25 and 1:125 dilution.

Figure 9: FACS binding-analysis of the 145-2C11 antibody on Jurkat cells transfected with the murine CD3 epsilon chain surface antigen. The FACS staining

was performed as described in Example 5, paragraph 2. The filled histogram represents cells incubated with the isotype control. The open histogram shows cells incubated with the 145-2C11 antibody.

- 5 Figure 10: FACS binding-analysis of the 145-2C11 antibody on untransfected Jurkat cells. The FACS staining was performed as described in Example 5, paragraph 2. The filled histogram represents cells incubated with the isotype control. The open histogram, superimposed on the filled histogram, represents cells incubated with the 145-2C11 antibody. 145-2C11 did not bind to Jurkat cells.
- 0
- Figure 11: FACS binding-analysis of the 145-2C11 antibody on CTLL2 cells. The FACS staining was performed as described in Example 5, paragraph 3. The filled histogram represents cells incubated with the isotype control. The open histogram indicates that the 145-2C11 antibody bound to CTLL2 cells.
- 5 The invention will now be described by reference to the following examples which are merely illustrative and are not to be construed as a limitation of the invention's scope.

Example 1: Construction of CD19xCD3 and CD3xCD19 single chain bispecific antibodies comprising various domain rearrangements.

- 0 Generally, bispecific single antibody chain molecules, each comprising a domain with binding specificity for the human CD3 antigen as well as a domain with binding specificity for the human CD19 antigen, were designed as set out in the following Table 1:
- 5 Table 1: Formats of bispecific single antibody chain molecules comprising anti-CD3 and anti-CD19 specificities

Construct Number	SEQ ID Nos (nuc/prot)	Formats of protein constructs (N → C)
1	29 / 30	VL(CD19)-VH(CD19)-VH(CD3)-VL(CD3)
2	1 / 2	VH(CD19)-VL(CD19)-VH(CD3)-VL(CD3)
3	3 / 4	VL(CD19)-VH(CD19)-VL(CD3)-VH(CD3)
4	5 / 6	VH(CD19)-VL(CD19)-VL(CD3)-VH(CD3)

5	7 / 8	VL(CD3)-VH(CD3)-VH(CD19)-VL(CD19)
6	9 / 10	VH(CD3)-VL(CD3)-VH(CD19)-VL(CD19)
7	11 / 12	VL(CD3)-VH(CD3)-VL(CD19)-VH(CD19)
8	13 / 14	VH(CD3)-VL(CD3)-VL(CD19)-VH(CD19)

The variable light-chain (VL) and variable heavy-chain (VH) domains from the HD37 hybridoma (Pezzutto, J. Immunol. 138 (1997), 2793-9) were cloned according to standard PCR methods (Orlandi, Proc. Natl. Acad. Sci. USA 86 (1989), 3833-7). cDNA synthesis was carried out with oligo dT primers and Taq polymerase. For the amplification of the anti-CD19 V domains via PCR, the primers 5' L1 (SEQ ID NO: 37) and 3' K (SEQ ID NO: 38), flanking the VL domain, and 5'H1 (SEQ ID NO: 39) and 3'G (SEQ ID NO: 40) for the heavy chain were used, based on primers described by Dübel, J. Immunol. Methods 175 (1994); 89-95. The cDNA of the anti-CD3 scFv fragment was kindly provided by Traunecker (Traunecker, EMBO J. 10 (1991) 3655-9).

Construct 1 as set out in Table 1 was constructed as follows. To obtain an anti-CD19 scFv-fragment, the corresponding VL- and VH-regions cloned into separate plasmid vectors, served as templates for a VL- and VH-specific PCR using the oligonucleotide primer pairs 5'VLB5RRV (SEQ ID NO: 41) / 3'VLGS15 (SEQ ID NO: 42) and 5'VHGS15 (SEQ ID NO: 43) / 3'VHBspE1 (SEQ ID NO: 28), respectively. Overlapping complementary sequences were introduced into the PCR-products that combined to form the coding sequence of 15-amino acid (Gly₄Ser₁)₃-linker during the subsequent fusion-PCR. This amplification step was performed with the primer pair 5'VLB5RRV (SEQ ID NO: 41) / 3'VHBspE1 (SEQ ID NO: 28) and the resulting fusion product (or rather anti-CD19 scFv-fragment) was cleaved with the restriction enzymes EcoRV and BspE1 and thus cloned into the bluescript KS-vector (Statagene), containing the (EcoR1/Sal1-cloned) coding sequence of the anti-17-1A/anti-CD3 bispecific single-chain antibody (actually the version without the Flag-tag) (Kufer, Cancer Immunol. Immunother. 45 (1997) 193). Thereby the anti-17-1A-specificity was replaced by the anti-CD19-scFV-fragment, preserving the 5-amino acid Gly₄Ser-linker that connects the C-terminal anti-CD3 scFv-fragment. Subsequently, the DNA-fragment encoding the anti-CD19/anti-CD3 bispecific single-chain antibody with the domain arrangement VL_{CD19}-VH_{CD19}-VH_{CD3}-VL_{CD3} was

subcloned into the EcoR1/Sal1 sites of the described expression vector pEF-DHFR (Mack, Proc. Natl. Acad. Sci. USA 92 (1995), 7021-5). The resulting plasmid-DNA was transfected into DHFR-deficient CHO-cells by electroporation. The selection, gene amplification and protein production were performed as previously described 5 (Mack, Proc. Natl. Acad. Sci. USA 92 (1995), 7021-5). The DNA sequence corresponding to construct 1 as set out above in Table 1 is as represented in SEQ ID NO: 29. The protein translation of this DNA sequence (without leader but including the stop codon) is as represented in SEQ ID NO: 30.

The remaining constructs as set out above in Table 1 were constructed as follows. 0 The DNA sequence corresponding to SEQ ID NO: 29, the protein translation of which (without leader but including the stop codon) is represented by SEQ ID NO: 30 was used as PCR template in designing the various anti-CD3 / anti-CD19 single chain bispecific antibodies set out above in Table 1.

To generate a VH-VL arrangement of CD19 in position A1 and A2 (as defined in 5 Figures 1A and 1B), PCR with the respective primer combination 5'VHCD19BsrGI (SEQ ID NO: 24) and 3'VHCD19GS15 (SEQ ID NO: 25) or 5'VLCD19GS15 (SEQ ID NO: 26) and 3'VLCD19BspEI (SEQ ID NO: 27) was used. During these PCR cycles overlapping complementary sequences were introduced into the PCR-products forming the coding sequence of a 15 amino acid linker during the subsequent fusion 0 PCR. The amplified VL and VH domains were fused in a second PCR reaction (fusion PCR) in which only the outer primers, namely 5'VHCD19BsrGI (SEQ ID NO: 24) and 3'VLCD19BspEI (SEQ ID NO: 27), and both amplicons were required.

A similar procedure employing other combinations of primers was used to construct other domain arrangements. A set of appropriate primers was designed to perform 5 multiple PCR-based cloning steps, finally resulting in the various VL-VH domain arrangements. The primer combinations used are listed in the following table:

Table 2: Overview of PCR-based cloning steps used for construction of positions A1 and A2 of constructs 2, 3, 4, 5, 6, 7 and 8 as shown in Table 1

PCR step	Primers Used	PCR step	Used Primers	Resulting N-terminal Domain order

PCR A1	5'VHCD19BsrGI (SEQ ID NO: 24)	3'VHCD19GS15 (SEQ ID NO: 25)	Fusion PCR A1+ A2	5'VHCD19BsrGI (SEQ ID NO: 24)	CD 19 VH-VL
PCR A2	5'VLCD19GS15 (SEQ ID NO: 26)	3'VLCD19BspEI (SEQ ID NO: 27)		3'VLCD19BspEI (SEQ ID NO: 27)	
PCR A1	5'VHL2KBsrGI (SEQ ID NO: 20)	3'VHL2KGS15 (SEQ ID NO: 21)	Fusion PCR A1 + A2	5'VHL2KBsrGI (SEQ ID NO: 20)	Anti-CD3 VH-VL
PCR A2	5' VLL2KGS15 (SEQ ID NO: 22)	3'VLL2KBspEI (SEQ ID NO: 23)		3'VLL2KBspEI (SEQ ID NO: 23)	
PCR A1	5'VLL2KBsrGI (SEQ ID NO: 31)	3'VLL2KGS15 (SEQ ID NO: 32)	Fusion PCR A1+ A2	5'VLL2KBsrGI (SEQ ID NO: 31)	Anti-CD3 VL-VH
PCR A2	5'VHL2KGS15 (SEQ ID NO: 33)	3'VHL2KBspEI (SEQ ID NO: 34)		3'VHL2KBspEI (SEQ ID NO: 34)	

In order to change the VH-VL domain arrangement in the C-terminal position, namely positions B1 and B2 as defined in Figures 1A and 1B, the following primers comprising the designated restriction enzyme recognition sites were designed to 5 perform the PCR-based cloning steps.

Table 3: Overview of PCR-based cloning steps used for construction of positions B1 and B2 of constructs 2, 3, 4, 5, 6, 7 and 8 as shown in Table 1

PCR step	Primers used		Resulting C-terminal domain order
PCR B1 + B2	5' VLCD19BspEIGS (SEQ ID NO: 19)	3' VHCD19BspEI (SEQ ID NO: 35)	CD 19 VL-VH
	5' VHCD19BspEIGS (SEQ ID NO: 17)	3'VLCD19BspEI (SEQ ID NO: 18)	CD19 VH-VL
	5' VLL2KBspEIGS (SEQ ID NO: 15)	3'VHL2KBspEI (SEQ ID NO: 16)	Anti-CD3 VL-VH

- 0 The corresponding PCR product, which was flanked by two BspEI sites, was cloned into a plasmid designated BS-CTI, which was digested with BspEI and XmaI restriction enzymes. A polylinker designated CTI (SEQ ID NO: 36) was inserted before into the Bluescript KS vector (GenBank accession number X52327) using the restriction enzyme cleavage sites XbaI and SalI in order to provide additional 5 cleavage sites as well as the sequence encoding a G₄S linker, six consecutive

histidine residues and a stop codon. During this cloning step the BspEI site of the VH domain was fused with the XmaI site of the plasmid thereby destroying both sites. The correct orientation of the variable domain was verified by sequencing according to standard protocols.

All molecular biological procedures indicated above were carried out according to standard protocols described in Sambrook, Molecular Cloning (A Laboratory Manual, 3rd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (2001).

DNA encoding the single chain bispecific antibodies in Table 1 (SEQ ID NOs: 29, 1, 3, 5, 7, 9, 11, 13) were transfected into DHFR deficient CHO cells for eukaryotic protein expression in DHFR deficient CHO cells as described in Mack et al. (Mack, Proc Natl Acad Sci USA 92 (1995), 7021-25). Gene amplification of the construct was induced by increasing concentrations of methotrexate (MTX) up to a final concentration of 20 nM MTX. The transfected cells were then expanded and 1 liter of supernatant produced.

Example 2: Expression and purification of the single chain bispecific antibodies directed against CD3 and CD19

The protein was expressed in chinese hamster ovary cells (CHO). Transfection of the expression vector was performed following calcium phosphate treatment of the cells ("Molecular Cloning", Sambrook et. al. 1989). The cells were grown in roller bottles with CHO modified DMEM medium (HiQ®, HiClone) for 7 days before harvest. The cells were removed by centrifugation and the supernatant containing the expressed protein was stored at -20°C.

Äkta® FPLC System (Pharmacia) and Unicorn® Software were used for chromatography. All chemicals were of research grade and purchased from Sigma (Deisenhofen) or Merck (Darmstadt). Immobilized metal affinity chromatography ("IMAC") was performed using a Fractogel® column (Merck) which was loaded with ZnCl₂ according to the protocol provided by the manufacturer. The column was equilibrated with buffer A2 (20 mM sodium phosphate buffer pH 7.5, 0.4 M NaCl) and the cell culture supernatant (500 ml) was applied to the column (10 ml) at a flow rate

of 3 ml/min. The column was washed with buffer A2 to remove unbound sample. Bound protein was eluted using a 2 step gradient of buffer B2 (20 mM sodium phosphate buffer pH 7.5, 0.4 M NaCl, 0.5 M Imidazol) according to the following:
Step 1: 20% buffer B2 in 6 column volumes;
5 Step 2: 100% buffer B2 in 6 column volumes.

Eluted protein fractions from step 2 were pooled for further purification.

Gel filtration chromatography was performed on a Sephadex S200 HiPrep column (Pharmacia) equilibrated with PBS (Gibco). Eluted protein samples (flow rate 1 ml/min) were subjected to standard SDS-PAGE and Western Blot for detection (see Figures 4 and 5). Prior to purification, the column was calibrated for molecular weight determination (molecular weight marker kit, Sigma MW GF-200). Protein concentrations were determined using protein assay dye (MicroBCA, Pierce) and IgG (Biorad) as standard protein.

5 The single chain bispecific antibodies were isolated in a two step purification process of IMAC (Figure 2) and gel filtration (Figure 3). The main product had a molecular weight of ca. 52 kDa under native conditions as determined by gel filtration in PBS. This molecular weight corresponds to the single chain bispecific antibody. All 0 constructs were purified according to this method. Construct #4 could not be purified from cell culture supernatants due to extremely low levels of specific protein expressed and secreted into the supernatant.

Purified bispecific protein was analyzed in SDS PAGE under reducing conditions 5 performed with pre-cast 4-12% Bis Tris gels (Invitrogen). Sample preparation and application were performed according to the protocol provided by the manufacturer. The molecular weight was determined with MultiMark protein standard (Invitrogen). The gel was stained with colloidal Coomassie (Invitrogen protocol). The purity of the isolated protein was >95% as determined by SDS-PAGE (Figure 4; protein band at 0 52 kD).

Western Blot was performed using an Optitran® BA-S83 membrane and the Invitrogen Blot Module according to the protocol provided by the manufacturer. The antibodies used were directed against the His Tag (Penta His, Qiagen) and Goat-

anti-mouse Ig labeled with alkaline phosphatase (AP) (Sigma), and BCIP/NBT (Sigma) as substrate. The single chain bispecific antibody could be specifically detected by Western Blot (Figure 5). A single band was detected at 52 kD corresponding to the purified bispecific molecule.

5

Example 3: Flow cytometric binding analysis of CD19xCD3 specific polypeptides

In order to test the functionality of the construct with regard to binding capability to CD19 and CD3, a FACS analysis was performed. For this purpose CD19 positive Nalm 6 cells (human B cell precursor leukemia) and CD3 positive Jurkat cells (human T cell leukemia) were used. 200,000 Nalm 6 cells and 200,000 Jurkat cells were respectively incubated for 30 min on ice with 50 µl of the pure cell supernatant of CHO cell cultures each expressing bispecific antibodies with different arrangements of VH and VL domains of CD19 and CD3 (as described in Example 2).

The cells were washed twice in PBS and binding of the construct was detected as follows. The cells treated as described above were contacted with an unlabeled murine Penta His antibody (diluted 1:20 in 50 µl PBS with 2% FCS; Qiagen; Order No. 34660), which specifically binds to cell-bound construct via the construct's C-terminal histidine tag. A washing step followed to remove unbound murine Penta His antibody. Bound anti His antibodies were detected with an Fc gamma-specific antibody (Dianova, order no. 115-116-071) conjugated to phycoerythrin, diluted 1:100 in 50 µl PBS with 2% FCS (thick grey line in Figures 6A-6F). As a negative control (thin black line in Figures 6A-6F) fresh culture medium was used in place of culture supernatant.

Cells were analyzed by flow cytometry on a FACS-Calibur apparatus (Becton Dickinson, Heidelberg). FACS staining and measuring of the fluorescence intensity were performed as described in Current Protocols in Immunology (Coligan, Kruisbeek, Margulies, Shevach and Strober, Wiley-Interscience, 2002). The binding ability of several domain arrangements were clearly detectable as shown for example in Figures 6B, 6D and 6F. In FACS analysis all constructs with different arrangement of VH and VL domains specific for CD19 and CD3 showed binding to CD3 compared to the negative control using culture medium and 1. and 2. detection antibody. Strong binding activity resulting in a shift in fluorescence intensity $>5 \times 10^1$ was observed for the constructs shown in Fig. 6A (#1), B (#2), D(#6), E (#7), F (#8). Weaker binding to

CD3 was observed for construct # 3 (Figure 6C). Strong binding to CD19 was observed for all constructs.

Example 4: Bioactivity of bispecific antibodies specific for CD19 and CD3

Cytotoxic activity of the bispecific antibodies with rearranged VH and VL domains was determined in a fluorochrome release based cytotoxicity assay.

CD19 positive NALM6 cells were used as target cells (1.5×10^7) labeled with 10 μ M calcein AM (Molecular Probes, Leiden, Netherland, no. C-1430) for 30 min at 37°C in cell culture medium. After two washes in cell culture medium, cells were counted and mixed with the CD4-positive T cell clone CB15 cells (kindly provided by Dr. Fickenscher, University of Erlangen/Nuernberg, Germany). 2×10^6 CB15 cells and 2×10^5 Nalm6 cells were mixed per ml (E:T ratio of 1:10) and 50 μ l of this suspension was used per well in a 96 well round bottom plate. Antibodies were diluted in RPMI/10% FCS to the required concentration and 50 μ l of this solution was added to the cell suspension. A standard reaction was incubated at 37°C/5% CO₂ for 2 hours. After the cytotoxic reaction, the released dye in the incubation medium can be quantitated in a fluorescence reader (Tecan, Crailsheim, Germany) and compared with the fluorescence signal from a control reaction (without bispecific antibody), and the fluorescence signal obtained for totally lysed cells (for 10 min in 1% saponin). On the basis of these readings, the specific cytotoxicity was calculated according to the following formula: [Fluorescence (Sample) - Fluorescence (Control)] : [Fluorescence (Total Lysis)- Fluorescence (Control)] x 100.

Sigmoidal dose response curves typically had R² values >0.97 as determined by Prism Software (GraphPad Software Inc., San Diego, USA). EC₅₀ values calculated by the analysis program were used for comparison of bioactivity.

As shown in Fig. 7 all constructs revealed cytotoxic activity against CD19 expressing NALM 6 cells. Strongest bioactivity was observed for constructs #2, 6, 8 and 1. Strong cytotoxic activity with EC 50 values < 500 pg/ml was detected for constructs #2, 6, 8 and 1. In addition to their high bioactivity, constructs #2 and #6 are also especially amenable to inclusion in pharmaceutical compositions. Constructs #3 and #7 showed EC 50 values of 52 ng/ml and 31 ng/ml respectively.

Example 5: The 145-2C11 antibody

The monoclonal antibody 145-2C11 directed against murine CD3 was analysed in different assays in order to characterize this antibody as group I or II anti-CD3 antibody. 145-2C11 was used by Brissinck, 1991, J.Immunol. 147-4019 for constructing a bispecific antibody directed against BCL-1 and murine CD3 and also by de Jonge, 1997, Cancer Immunol. Immunother. 45-162.

5.1. Binding of 145-2C11 to the recombinant, purified extracellular domain of the murine CD3 epsilon chain in ELISA

The anti-murine CD3 epsilon antibody (145-2C11 BD biosciences, Heidelberg, FRG) was coated (50µl at 5µg/ml in PBS) on a Maxisorp ELISA plate (Nunc GmbH, Wiesbaden, FRG). After overnight incubation unspecific binding was blocked with 1,5% BSA in PBS for 1 hour. After washing three times with 200 µl PBS, different dilutions of the recombinant C-terminally His6-tagged CD3 protein (obtained by a procedure analogous to that described in Example 6 for obtaining recombinant human CD3-epsilon) and an irrelevant antigen (BSA) were incubated for 1 hour in the prepared cavities of the plate. Binding of recombinant CD3 was detected with horseradish peroxidase conjugated anti-His antibody (Roche Diagnostics GmbH, Mannheim, FRG; diluted 1:500 in 1,5% BSA in PBS) binding to a polyhistidine tag. ABTS (2,2'-Azino-di[3-ethylbenzthiazoline sulfonate (6)] diammonium salt, Roche Diagnostics GmbH, Mannheim, FRG) was used as substrate according to the specifications of the manufacturer. The absorbance values were measured on a SPECTRAFluor Plus photometer (Tecan Deutschland GmbH, Crailsheim). The measurement wavelength was 405 nm, the reference wavelength was 620 nm. XFLUOR4 Version: V 4.40 for Windows was used as analysis software. Specific binding of the recombinant, purified extracellular domain of the murine CD3 epsilon chain to the 145-2C11 antibody was detected for antibody dilutions of 1:5 and 1:25. (Figure 8).

0

5.2. Binding of 145-2C11 to a human T cell line transfected with the murine CD3 epsilon chain in FACS

Binding of 145-2C11 antibody to Jurkat cells (obtained from ATCC) transfected with the murine CD3 epsilon chain surface antigen was tested using an FACS assay. To

For this end, 2.5×10^5 cells were incubated with a 1:50 dilution of the PE-conjugated 145-2C11 antibody (BD biosciences, Heidelberg, FRG) in 50 μ l PBS with 2%FCS. As a control another sample of cells was incubated with a 1:50 dilution of a PE-conjugated hamster IgG group1 Kappa isotype control (BD biosciences, Heidelberg, FRG) in 50 μ l PBS with 2%FCS. Untransfected cells were also assayed under the described conditions. The samples were measured on a FACSscan (BD biosciences, Heidelberg, FRG). Specific binding of the 145-2C11 antibody as compared to the isotype control was clearly detectable on the transfected but not on the untransfected cells (Figures 9 and 10) inducing a shift in fluorescence intensity.

5.3. Binding of 145-2C11 to a murine T cell line in FACS

Binding of 145-2C11 antibody to CTLL2 cells (obtained from ATCC) was tested using an FACS assay. 2.5×10^5 cells were incubated with a 1:50 dilution of the PE-conjugated 145-2C11 antibody (BD biosciences, Heidelberg, FRG) in 50 μ l PBS with 2%FCS. As a control another aliquot of cells was incubated with a 1:50 dilution of a PE-conjugated hamster IgG group1 Kappa isotype control (BD biosciences, Heidelberg, FRG) in 50 μ l PBS with 2%FCS. The samples were measured on a FACSscan (BD biosciences, Heidelberg, FRG). Specific binding of the 145-2C11 antibody as compared to the isotype control was clearly detectable (Figure 11).

In summary, these data clearly showed that murine anti CD3 antibody 145-2C11 recognized purified recombinant CD3 epsilon as well as murine CD3 epsilon expressed in eukaryotic cells. 145-2C11 bound to Jurkat cells transfected with murine CD3 epsilon as well as to a murine T cell line expressing the CD3 epsilon chain in its native murine TCR receptor complex. Both cell lines express CD3 epsilon on the cell surface in the context of other TCR subunits. These two criteria - binding to purified recombinant CD3 epsilon as well as binding to cells expressing CD3 epsilon in the TCR complex - were described as the essential features of anti CD3 antibodies belonging to "group I" according to the classification described by Tunnacliffe et al. (Tunnacliffe, 1989, Int. Immunol., 1, 546-550). In contrast, "group II" antibodies specifically bind to epitopes the conformations of which are dependent on the whole T cell receptor complex. According to these definitions 145-2C11 could clearly be classified as an anti CD3 antibody belonging to "group I". This confirms the observations of Leo, Proc. Natl. Acad. Sci USA (1987), 1374, who found that 145-

2C11 could still bind to CD3 epsilon when it was dissociated by detergent treatment from the other chains of the CD3- and T cell receptor-complex, thus revealing a "group I" CD3 binding pattern.

5 Example 6: Assignment of CD3-reactive bispecific single-chain antibodies to different CD3-binding patterns

CD3-reactive bispecific single-chain antibodies may be assigned to different CD3-binding patterns according to the classification of Tunnacliffe, International Immunology 1 (1989), 546. In order to assign a CD3-reactive bispecific single-chain antibody to the "group I" CD3-binding pattern an ELISA may be carried out with purified recombinant human CD3-epsilon. Recombinant human CD3-epsilon may be e.g. obtained as C-kappa-fusion construct as described by Tunnacliffe, Immunol. Lett. 21 (1989) 243 or as truncated soluble CD3-epsilon available according to the following procedure:

cDNA was isolated from human peripheral blood mononuclear cells. Preparation of the cells was performed according to standard protocols (Current Protocols in Immunology (Coligan, Kruisbeek; Margulies, Shevach and Strober, John Wiley & Sons, Inc., USA, 2002)). The isolation of total RNA and cDNA synthesis by random-primed reverse transcription was performed according to standard protocols (Sambrook, Molecular Cloning; Laboratory Manual, 2nd edition, Cold Spring Harbor laboratory Press, Cold Spring Harbor, New York (1989)). PCR was used to amplify the coding sequence of the extracellular domain of the human CD3 epsilon chain. The primers used in the PCR were designed so as to introduce restriction sites at the beginning and the end of the cDNA coding for the extracellular portion of the human CD3 epsilon chain (SEQ ID NO: 80 and SEQ ID NO:81). The introduced restriction sites, BsrGI and BspEI, were utilised in the following cloning procedures. The PCR product was then cloned via BsrGI and BspEI into a plasmid designated BS-Fss-Lsp derived from the Bluescript KS⁺ cloning vector (Stratagene Europe, Amsterdam-Zuidhoost, the Netherlands) following standard protocols. (The vector was generated by cloning a DNA fragment (SEQ ID NO: 82) via EcoRI and Sall into Bluescript KS⁺.) The sequence of different clones was determined by sequencing according to standard protocols. By cloning into BS-Fss-Lsp the coding sequence of a murine

immunoglobulin heavy chain leader peptide was fused in-frame to the 5' end of the coding sequence for the extracellular portion of the human CD3 epsilon chain. The cDNA was then cloned via EcoRI and BspEI into another plasmid designated as BSCTI to attach a sequence to the C-terminus, coding for a polyhistidine tag of six consecutive histidine residues followed by a stop codon (BSCTI is described in Kufer, Cancer Immunity 1 (2001), 10). In this step the BspEI site of the cDNA was fused into an XmaI site of the plasmid thereby destroying both sites. All cloning steps were designed so as to generate an intact reading frame for the construct. The plasmid now contained a sequence coding for a protein comprising a murine immunoglobulin heavy chain leader peptide, to allow for secreted expression, followed by the extracellular domain of the human CD3 epsilon chain followed by a polyhistidine tag of six consecutive histidine residues, to allow for purification and detection via the polyhistidine tag (SEQ ID NO: 78 and SEQ ID NO: 79). This sequence was then cloned into the plasmid pFastBac1TM (Invitrogen GmbH, Karlsruhe, FRG) via EcoRI and SalI.

Expression of the extracellular domain of the human CD3 epsilon chain in High FiveTM cells was performed using the *Bac-to-Bac[®] Baculovirus Expression System* (Invitrogen GmbH, Karlsruhe, FRG) according to the specifications of the manufacturer. 10 litres of supernatant in batches of 500 ml were produced. The construct was then purified out of the culture supernatant. Purification was performed as a two-step purification. First the diluted supernatants were loaded on ion exchange columns. The fractionated eluate was tested in an ELISA assay. To this end, an anti-human CD3 epsilon antibody (UCHT1 BD biosciences, Heidelberg, FRG) was coated (50 µl at 5 µg/ml in PBS) on a Maxisorp ELISA plate (Nunc GmbH, Wiesbaden, FRG) overnight. Unspecific binding was blocked with 1.5 % BSA in PBS for 1 hour. All prior and subsequent washing steps were performed three times with 200 µl PBS. Afterwards, eluate fractions were incubated for 1 hour in the prepared cavities of the plate. Detection of the recombinant protein was performed with a horseradish peroxidase conjugated anti-His antibody (Roche Diagnostics GmbH, Mannheim, FRG; 50 µl of antibody diluted 1:500 in 1.5 % BSA in PBS). Development of the ELISA was performed with ABTS (2,2'-Azino-bis(3-Ethylbenz-Thiazolin)-6-Sulfonic acid) Roche Diagnostics GmbH, Mannheim, FRG) according to the specifications of the manufacturer. Positive fractions were further purified over a

cobalt-chelate column which preferentially binds histidine-tagged proteins. Eluate fractions were tested using the described ELISA assay. Positive fractions were pooled and concentrated.

- 5 For assignment of CD3-reactive bispecific single-chain antibodies to the "group I" CD3-binding pattern, purified recombinant human CD3-epsilon may be coated (50 µl at 10 µg/ml in PBS) on a Maxisorp ELISA plate (Nunc GmbH, Wiesbaden, FRG) overnight and unspecific binding subsequently blocked with 1,5% BSA in PBS for 1 hour. Next the ELISA wells are washed three times with 200 µl PBS. Then purified
0 CD3-reactive bispecific single-chain antibody (50 µl at 10 µg/ml in 1,5% BSA in PBS) in a version, that (i) contains an N-terminal FLAG-tag with the amino acid sequence: dykdddk (obtainable e.g. as described in Mack, PNAS 92 (1995) 7021) but (ii) avoids a polyhistidine tag can be incubated for 1 hour on immobilized CD3-epsilon. As negative control 50 µl 1,5% BSA in PBS without bispecific single-chain antibody
5 may be used. As positive control the "group I" anti-CD3 antibody UCHT1 (BD biosciences, Heidelberg, FRG; 50 µl of antibody diluted to 5 µg/ml in 1,5% BSA in PBS) may be incubated on immobilized CD3-epsilon. After another washing step carried out as above, bispecific single-chain antibody specifically bound to human CD3-epsilon can be detected with an unconjugated anti-FLAG antibody (ANTI-FLAG
0 M2 obtained from Sigma-Aldrich Chemie GmbH, Taufkirchen FRG; 50 µl of antibody diluted to 5 µg/ml in 1,5% BSA in PBS) followed by a horseradish peroxidase-conjugated, goat anti-mouse IgG, Fc-gamma fragment specific antibody (obtained from Dianova, Hamburg, FRG; diluted 1:1000 in 50 µl PBS with 1,5% BSA), which directly detects the control antibody bound to immobilized CD3-epsilon. Development
5 of the ELISA was carried out with ABTS (Roche Diagnostics GmbH, Mannheim, FRG) for 90 minutes in accordance with the specifications of the manufacturer. In contrast to the control antibody UCHT-1 none of the bispecific single-chain antibodies based on the CD3-binding specificity described by Traunecker, EMBO J. 10 (1991) 3655 showed specific interaction with purified recombinant human CD3-epsilon, thus
0 excluding assignment to the "group I" CD3-binding pattern. Differentiation between the "group II" and the "group III" CD3-binding patterns may be carried out by flowcytometric binding analysis of CD3-reactive bispecific single-chain antibodies on human T cells and human CD3-epsilon-transgenic murine T cells as described e.g. in Tunnacliffe, International Immunology 1(1989) 546. Flowcytometry may be carried

out as described in Example 3 of the present invention if the bispecific single-chain antibody to be analyzed carries a polyhistidine-tag or according to the same protocol, except that the detection antibody is replaced by a fluorescence-labeled anti-Flag antibody if the bispecific single-chain antibody is Flag-tagged.

Claims

1. A pharmaceutical composition comprising a bispecific single chain antibody construct, said bispecific single chain antibody construct comprising binding domains specific for human CD3 and human CD19, wherein the corresponding variable heavy chain regions (V_H) and the corresponding variable light chain regions (V_L) regions are arranged, from N-terminus to C-terminus, in the order,
 - $V_H(CD19)-V_L(CD19)-V_H(CD3)-V_L(CD3),$
 - $V_H(CD3)-V_L(CD3)-V_H(CD19)-V_L(CD19)$ or
 - $V_H(CD3)-V_L(CD3)-V_L(CD19)-V_H(CD19).$
2. The pharmaceutical composition of claim 1, wherein said V_H and V_L regions of said CD3 specific domain are derived from an CD3 specific antibody selected from the group consisting of: OKT-3, X35-3, VIT3, BMA030 (BW264/56), CLB-T3/3, CRIS7, YTH12.5, F111-409, CLB-T3.4.2, TR-66, WT31, WT32, SPv-T3b, 11D8, XIII-141, XIII-46, XIII-87, 12F6, T3/RW2-8C8, T3/RW2-4B6, OKT3D, M-T301, SMC2 and F101.01.
3. The pharmaceutical composition of claim 1 or 2, wherein said V_H region comprises at least one CDR3 region comprising the amino acid sequence: SEQ ID NO. 54 or 77.
4. The pharmaceutical composition of claim 1 or 2, wherein said V_H region comprises at least one CDR2 region comprising the amino acid sequence: SEQ ID NO. 53 or 76.
5. The pharmaceutical composition of claim 1 or 2, wherein said V_H region comprises at least one CDR1 region comprising the amino acid sequence: SEQ ID NO. 52 or 75.
6. The pharmaceutical composition of any one of claims 1 to 5, wherein said V_L region comprises at least one CDR3 region comprising the amino acid sequence: SEQ ID NO. 57 or 74.

7. The pharmaceutical composition of any one of claims 1 to 5, wherein said V_L region comprises at least one CDR2 region comprising the amino acid sequence: SEQ ID NO. 56 or 73.
8. The pharmaceutical composition of any one of claims 1 to 5, wherein said V_L region comprises at least one CDR1 region comprising the amino acid sequence: SEQ ID NO. 55 or 72.
9. The pharmaceutical composition of any of claims 1 to 8, wherein said bispecific single chain antibody construct comprises an amino acid sequence selected from the group consisting of
 - (a) an amino acid sequence as depicted in SEQ ID NOS 2, 10 or 14;
 - (b) an amino acid sequence encoded by a nucleic acid sequence as shown in SEQ ID NOS 1, 9 or 13;
 - (c) an amino acid sequence encoded by a nucleic acid sequence hybridizing under stringent conditions to the complementary nucleic acid sequence of (b); and
 - (d) an amino acid sequence encoded by a nucleic acid sequence which is degenerate as a result of the genetic code to a nucleotide sequence of (b).
10. The pharmaceutical composition of any of claims 1 to 9, wherein said variable domains are connected by additional linker sequences.
11. A pharmaceutical composition comprising a nucleic acid sequence encoding a bispecific single chain antibody construct as defined in any of claims 1 to 10.
12. A pharmaceutical composition comprising a vector which comprises a nucleic acid sequence as defined in claim 11.
13. The pharmaceutical composition of claim 12, wherein said vector further comprises a regulatory sequence which is operably linked to said nucleic acid sequence nucleic acid sequence defined in claim 11.

14. The pharmaceutical composition of claim 12 or 13, wherein said vector is an expression vector.
- 5 15. A pharmaceutical composition comprising a host transformed or transfected with a vector defined in any of claims 12 to 14.
-) 16. A pharmaceutical composition according to any of claims 1 to 15, further comprising a proteinaceous compound capable of providing an activation signal for immune effector cells.
- (17. A process for the production of a pharmaceutical composition according to any of claims 1 to 16, said process comprising culturing a host defined in claim 15 under conditions allowing the expression of the bispecific single chain antibody construct as defined in any of claims 1 to 10 and recovering the produced bispecific single chain antibody construct from the culture.
-) 18. Use of a bispecific single chain antibody construct as defined in any of claims 1 to 10, a nucleic acid sequence as defined in claim 11, a vector as defined in any of claims 12 to 14 and/or a host as defined in claim 15 for the preparation of a pharmaceutical composition for the prevention, treatment or amelioration of a proliferative disease, a minimal residual cancer, a tumorous disease, an inflammatory disease, an immunological disorder, an autoimmune disease, an infectious disease, a viral disease, allergic reactions, parasitic reactions, graft-versus-host diseases host-versus-graft diseases or B-cell malignancies, wherein said pharmaceutical composition optionally further comprises a proteinaceous compound capable of providing an activation signal for immune effector cells.
-) 19. A method for the prevention, treatment or amelioration of a proliferative disease, a minimal residual cancer, a tumorous disease, an inflammatory disease, an immunological disorder, an autoimmune disease, an infectious disease, viral disease, allergic reactions, parasitic reactions, graft-versus-host diseases or host-versus-graft diseases or B cell malignancies comprising the

step of administering to a subject in need of such a prevention, treatment or amelioration a pharmaceutical composition of any of claim 1 to 16.

20. The method of claim 19, wherein said subject is a human.
5
21. The use of claim 18 or the method of claim 19 or 20, wherein said tumorous disease is selected from the group consisting of lymphoma, B-cell leukemias or Hodgkin lymphoma.
-) 22. Use of a bispecific single chain antibody construct as defined in any of claims 1 to 10, a nucleic acid sequence as defined in claim 11, a vector as defined in any of claims 12 to 14 and/or a host as defined in claim 15 for the preparation of a pharmaceutical composition for depletion of B-cells
C
23. The use of claim 18 or the method of claim 19 or 20, wherein said B-Cell malignancy is non-Hodgkin lymphoma.
5
24. The use of claim 18 or the method of claim 19 or 20, wherein said autoimmune disease is rheumatoid arthritis.
C
25. A kit comprising a bispecific single chain antibody construct as defined in any of claims 1 to 10, a nucleic acid sequence as defined in claim 11, a vector as defined in any of claims 12 to 14 and/or a host as defined in claim 15.
C

Figure 1A




Figure 1B





Figure 2









Figure 3

Figure 4**Figure 5**


construct #1

Figure 6A




construct #2

Figure 6B




construct #3

Figure 6C




construct #6

Figure 6D



construct #7

Figure 6E



construct #8

Figure 6F






Figure 7

Figure 8



145-2C11+irr. antigen




Figure 9**Figure 10**

Figure 11



1
SEQUENCE LISTING

<110> Micromet AG

<120> Pharmaceutical compositions for the treatment of B-cell related disorders

<130> H1589 PCT

<150> EP 03012136.2

<151> 2003-05-31

<160> 82

<170> PatentIn version 3.1

<210> 1

<211> 1533

<212> DNA

<213> artificial sequence

<220>

<223> Nucleotide sequence of CD19 VH/VL x CD3 VH/VL (BsrG I to Sal I)

<400> 1

tgtacactcc	caggtgcagc	tgcagcagtc	tggggctgag	ctgggtgaggc	ctgggtcctc	60
agtgaagatt	tcctgcaagg	cttctggcta	tgcattcagt	agctactgga	tgaactgggt	120
gaagcagagg	cctggacagg	gtcttgagtg	gattggacag	atttggcctg	gagatggta	180
tactaactac	aatggaaagt	tcaagggtaa	agccactctg	actgcagacg	aatcctccag	240
cacagcctac	atgcaactca	gcagccttagc	atctgaggac	tctgcggct	atttctgtgc	300
aagacgggag	actacgacgg	taggccgtta	ttactatgct	atggactact	ggggccaagg	360
gaccacggc	accgtctcct	ccgggtggtgg	tggttctggc	ggcgccggct	ccgggtggtgg	420
tggttctgat	atccagctga	cccagtctcc	agcttctttg	gctgtgtctc	tagggcagag	480
ggccaccatc	tcctgcaagg	ccagccaaag	tgttgattat	gatgggtata	gttatttcaa	540
ctggcacca	cagattccag	gacagccacc	caaactcctc	atctatgtg	catccaatct	600
agtttctgg	atcccaccca	ggtttagtgg	cagtgggtct	gggacagact	tcaccctcaa	660
catccatcct	gtggagaagg	tggatgctgc	aacctatcac	tgtcagcaa	gtactgagga	720

tccgtggacg ttcgggtggag ggaccaagct cgagatcaa ² tccggaggtg gtggatccga	780
tatcaaactg cagcagtcag gggctgaact ggcaagacct ggggcctcag tgaagatgtc	840
ctgcaagact tctggctaca cctttactag gtacacgatg cactggtaa aacagaggcc	900
tggacagggt ctggaatgga ttggatacat taatccttagc cgtggttata ctaattacaa	960
tcagaagttc aaggacaagg ccacattgac tacagacaaa tcctccagca cagcctacat	1020
gcaactgagc agcctgacat ctgaggactc tgcagtctat tactgtgcaa gatattatga	1080
tgatcattac tgcccttgact actggggcca aggaccact ctcacagtct cctcagtcga	1140
aggtggaagt ggaggttctg gtggaagtgg aggttcaggt ggagtcgacg acattcagct	1200
gaccaggctccagcaatca tgtctgcac tccagggag aaggtcacca tgacctgcag	1260
agccagttca agtgtaaattt acatgaactg gtaccagcag aagttagggca cctccccaa	1320
aagatggatt tatgacacat ccaaagtggc ttctggagtc ctttatcgct tcagtggcag	1380
tgggtctggg acctcatact ctctcacaat cagcagcatg gaggctgaag atgctgccac	1440
ttattactgc caacagtgga gtagtaaccc gctcacgttc ggtgctggga ccaagctgga	1500
gctgaaacat catcaccatc atcattagtc gac	1533

<210> 2

<211> 505

<212> PRT

<213> artificial sequence

<220>

<223> Translation of CD19 VH/VL x CD3 VH/VL (mature protein w/o Leader)

<400> 2

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ser			
1	5	10	15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Tyr		
20	25	30

Trp Met Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile		
35	40	45

Gly Gln Ile Trp Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe		
50	55	60

Lys Gly Lys Ala Thr Leu Thr Ala Asp Glu Ser Ser Ser Thr Ala Tyr			
65	70	75	80

Met Gln Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Phe Cys		
85	90	95

Ala Arg Arg Glu Thr Thr Thr Val Gly Arg Tyr Tyr Tyr Ala Met Asp
100 105 3
Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly
115 120 125
Ser Gly Gly Gly Ser Gly Gly Gly Ser Asp Ile Gln Leu Thr
130 135 140
Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile
145 150 155 160
Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp Gly Asp Ser Tyr Leu
165 170 175
Asn Trp Tyr Gln Gln Ile Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr
180 185 190
Asp Ala Ser Asn Leu Val Ser Gly Ile Pro Pro Arg Phe Ser Gly Ser
195 200 205
Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Lys Val
210 215 220
Asp Ala Ala Thr Tyr His Cys Gln Gln Ser Thr Glu Asp Pro Trp Thr
225 230 235 240
Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Ser Gly Gly Gly Ser
245 250 255
Asp Ile Lys Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala
260 265 270
Ser Val Lys Met Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Arg Tyr
275 280 285
Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
290 295 300
Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Phe
305 310 315 320
Lys Asp Lys Ala Thr Leu Thr Thr Asp Lys Ser Ser Ser Thr Ala Tyr
325 330 335
Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
340 345 350
Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr Trp Gly Gln Gly
355 360 365
Thr Thr Leu Thr Val Ser Ser Val Glu Gly Gly Ser Gly Gly Ser Gly

4

370	375	380
-----	-----	-----

Gly Ser Gly Ser Gly Gly Val Asp Asp Ile Gln Leu Thr Gln Ser
 385 390 395 400

Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys
 405 410 415

Arg Ala Ser Ser Ser Val Ser Tyr Met Asn Trp Tyr Gln Gln Lys Ser
 420 425 430

Gly Thr Ser Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Val Ala Ser
 435 440 445

Gly Val Pro Tyr Arg Phe Ser Gly Ser Gly Thr Ser Tyr Ser
 450 455 460

Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys
 465 470 475 480

Gln Gln Trp Ser Ser Asn Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu
 485 490 495

Glu Leu Lys His His His His His His
 500 505

<210> 3

<211> 1525

<212> DNA

<213> artificial sequence

<220>

<223> Nucleotide sequence of CD19 VL/VH x CD3 VL/VH (BsrG I to Sal I)

<400> 3 tgtacactcc gatatccagc tgaccaggc tccagttct ttggctgtgt ctctaggca	60
gagggccacc atctcctgca aggccagcca aagtgttcat tatgtatggtg atagttattt	120
gaactggtaç caacagattc caggacagcc acccaaactc ctcatctatg atgcattccaa	180
tctagttct gggatcccac ccaggttag tggcagtggg tctggacag acttcaccct	240
caacatccat cctgtggaga aggtggatgc tgcaacctat cactgtcagc aaagtactga	300
ggatccgtgg acgttcggtg gagggaccaa gctcgagatc aaaggtggtg gtggttctgg	360
cggcggcggc tccgggtggt gttgttctca ggtgcagctg cagcagtctg gggctgagct	420
ggtgaggcct ggttcctcag tgaagatttc ctgcaaggct tctggctatg cattcagtag	480
ctactggatg aactgggtga agcagaggcc tggacagggc cttgagtgaa ttggacagat	540
ttggcctgga gatggtgata ctaactacaa tggaaagttc aagggtaaag ccactctgac	600

tgcagacgaa tcctccagca cagcctacat gcaactcagc agcctagcat ctgaggactc	660
tgcggtctat ttctgtgcaa gacgggagac tacgacggta ggccgttatt actatgctat	720
ggactactgg gcccaaggga ccacggtcac cgtctcctcc ggaggtggtg gatccgacat	780
tcagctgacc cagtctccag caatcatgtc tgcatctcca gggagaagg tcaccatgac	840
ctgcagagcc agttcaagtg taagttacat gaactggtag cagcagaagt caggcaccc	900
ccccaaaaga tggatttatg acacatccaa agtggcttct ggagtccctt atcgcttcag	960
tggcagtggg tctgggacct catactctct cacaatcagc agcatggagg ctgaagatgc	1020
tgccacttat tactgccaac agtggagtag taacccgctc acgttcggtg ctgggaccaa	1080
gctggagctg aaaggtggtg gtggttctgg cggcggcggc tccgggtggtg gtggttctga	1140
tatcaaactg cagcagtcag gggctgaact ggcaagaccc gggcctcag tgaagatgtc	1200
ctgcaagact tctggctaca ccttactag gtacacgatg cactggtaa aacagaggcc	1260
tggacagggc ctggaatgga ttggatacat taatccttagc cgtggttata ctaattacaa	1320
tcagaagttc aaggacaagg ccacattgac tacagacaaa tcctccagca cagcctacat	1380
gcaactgagc agcctgacat ctgaggactc tgcaagtctat tactgtgcaa gatattatga	1440
tgatcattac tgccttgact actggggcca aggaccact ctcacagtct cctccggca	1500
tcatcaccat catcattgag tcgac	1525

<210> 4

<211> 502

<212> PRT

<213> artificial sequence

<220>

<223> Translation of CD19 VL/VH x CD3 VL/VH (mature protein w/o Leader)

<400> 4

Asp Ile Gln Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly			
1	5	10	15

Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp		
20	25	30

Gly Asp Ser Tyr Leu Asn Trp Tyr Gln Gln Ile Pro Gly Gln Pro Pro		
35	40	45

Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Val Ser Gly Ile Pro Pro		
50	55	60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His.			
65	70	75	80

Pro Val Glu Lys Val Asp Ala Ala Thr Tyr His Cys Gln Gln Ser Thr
85 90 95

Glu Asp Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Gly
100 105 110

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gln Val
115 120 125

Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ser Ser Val
130 135 140

Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Tyr Trp Met
145 150 155 160

Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Gln
165 170 175

Ile Trp Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys Gly
180 185 190

Lys Ala Thr Leu Thr Ala Asp Glu Ser Ser Ser Thr Ala Tyr Met Gln
195 200 205

Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg
210 215 220

Arg Glu Thr Thr Thr Val Gly Arg Tyr Tyr Tyr Ala Met Asp Tyr Trp
225 230 235 240

Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Ser Asp
245 250 255

Ile Gln Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu
260 265 270

Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Met Asn
275 280 285

Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr Asp
290 295 300

Thr Ser Lys Val Ala Ser Gly Val Pro Tyr Arg Phe Ser Gly Ser Gly
305 310 315 320

Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp
325 330 335

Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Leu Thr Phe
340 345 350

Gly Ala Gly Thr Lys Leu Glu Leu Lys Gly⁷ Gly Gly Ser Gly Gly
 355 360 365

Gly Gly Ser Gly Gly Ser Asp Ile Lys Leu Gln Gln Ser Gly
 370 375 380

Ala Glu Leu Ala Arg Pro Gly Ala Ser Val Lys Met Ser Cys Lys Thr
 385 390 395 400

Ser Gly Tyr Thr Phe Thr Arg Tyr Thr Met His Trp Val Lys Gln Arg
 405 410 415

Pro Gly Gln Gly Leu Glu Trp Ile Gly Tyr Ile Asn Pro Ser Arg Gly
 420 425 430

Tyr Thr Asn Tyr Asn Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr Thr
 435 440 445

Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser
 450 455 460

Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Tyr Tyr Asp Asp His Tyr
 465 470 475 480

Cys Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Gly
 485 490 495

His His His His His His
 500

<210> 5

<211> 1528

<212> DNA

<213> artificial sequence

<220>

<223> Nucleotide sequence of CD19 VH/VL x CD3 VL/VH (BsrG I to Sal I)

<400> 5	
tgtacactcc caggtgcagc tgcagcagtc tggggctgag ctggtgaggc ctgggtcctc	60
agtgaagatt tcctgcaagg cttctggcta tgcattcagt agctactgga tgaactgggt	120
gaagcagagg cctggacagg gtcttgagtg gattggacag atttggcctg gagatggta	180
tactaactac aatggaaagt tcaagggtaa agccactctg actgcagacg aatcctccag	240
cacagcctac atgcaactca gcagcctagc atctgaggac tctgcggctt atttctgtgc	300
aagacgggag actacgacgg taggccgtta ttactatgct atggactact gggcccaagg	360
gaccacggtc accgtctcct ccgggtgggtgg tggttctggc ggccggcggtct ccgggtgggtgg	420

8

tggttctgat atccagactga cccagtctcc agcttcttg gctgtgtc tagggcagag 480
ggccaccatc tcctgcaagg ccagccaaag tggattat gatggtgata gttatttcaa 540
ctggcacaa cagattccag gacagccacc caaactcctc atctatgatg catccaatct 600
agtttctggg atcccaccca gtttagtgg cagtggtct gggacagact tcaccctcaa 660
catccatcct gtggagaagg tggatgcgc aacctatcac tgtcagcaaa gtactgagga 720
tccgtggacg ttccggtagg ggaccaagct cgagatcaaa tccggaggtg gtggatccga 780
cattcagctg acccagtctc cagcaatcat gtctgcatac ccagggaga aggtcaccat 840
gacctgcaga gccagttcaa gtgttaactt catgaactgg taccagcaga agtcaggcac 900
ctcccccaaa agatggattt atgacacatc caaagtggct tctggagtcc cttatcgctt 960
cagtggcagt gggctggga cctcataactc tctcacaatc agcagcatgg aggctgaaga 1020
tgctgccact tattactgcc aacagtggag tagtaacccg ctcacgttcg gtgctggac 1080
caagctggag ctgaaaggtg gtgggtttc tggcggcggc ggctccggtg gtgggtttc 1140
tgatatcaaa ctgcagcagt cagggctga actggcaaga cctgggcct cagtgaagat 1200
gtcctgcaag acttctggct acaccttac tagtacacg atgcactggg taaaacagag 1260
gcctggacag ggtctggaaat ggattggata cattaatcct agccgtggtt atactaatta 1320
caatcagaag ttcaaggaca aggccacatt gactacagac aaatcctcca gcacagccta 1380
catgcaactg agcagcctga catctgagga ctctgcagtc tattactgtg caagatatta 1440
tcatgtatcat tactgccttg actactgggg ccaaggcacc actctcacag tctcctccgg 1500
qcatcatcac catcatcatt gagtcgac 1528

<210> 6

<211> 503

<212> PRT

<213> artificial sequence

<220>

<223> Translation of CD19 VH/VL x CD3' VL/VH (mature protein w/o Leader)

<400> 6

Gln val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ser
1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Tyr
20 25 30

Trp Met Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Glu Ile Trp Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe
50 55 60

Lys Gly Lys Ala Thr Leu Thr Ala Asp Glu Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met Gln Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Phe Cys
85 90 95

Ala Arg Arg Glu Thr Thr Val Gly Arg Tyr Tyr Tyr Ala Met Asp
100 105 110

Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly
115 120 125

Ser Gly Gly Gly Ser Gly Gly Gly Ser Asp Ile Gln Leu Thr
130 135 140

Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile
145 150 155 160

Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp Gly Asp Ser Tyr Leu
165 170 175

Asn Trp Tyr Gln Gln Ile Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr
180 185 190

Asp Ala Ser Asn Leu Val Ser Gly Ile Pro Pro Arg Phe Ser Gly Ser
195 200 205

Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Lys Val
210 215 220

Asp Ala Ala Thr Tyr His Cys Gln Gln Ser Thr Glu Asp Pro Trp Thr
225 230 235 240

Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Ser Gly Gly Gly Ser
245 250 255

Asp Ile Gln Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly
260 265 270

Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Met
275 280 285

Asn Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr
290 295 300

Asp Thr Ser Lys Val Ala Ser Gly Val Pro Tyr Arg Phe Ser Gly Ser
305 310 315 320

Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu
325 330 335

10

Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Leu Thr
 340 345 350

Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Gly Gly Gly Ser Gly
 355 360 365

Gly Gly Gly Ser Gly Gly Ser Asp Ile Lys Leu Gln Gln Ser
 370 375 380

Gly Ala Glu Leu Ala Arg Pro Gly Ala Ser Val Lys Met Ser Cys Lys
 385 390 395 400

Thr Ser Gly Tyr Thr Phe Thr Arg Tyr Thr Met His Trp Val Lys Gln
 405 410 415

Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Tyr Ile Asn Pro Ser Arg
 420 425 430

Gly Tyr Thr Asn Tyr Asn Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr
 435 440 445

Thr Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr
 450 455 460

Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Tyr Tyr Asp Asp His
 465 470 475 480

Tyr Cys Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser
 485 490 495

Gly His His His His His
 500

<210> 7

<211> 1531

<212> DNA

<213> artificial sequence

<220>

<223> Nucleotide sequence of CD3 VL/VH x CD19 VH/VL (BsrG I to Sal I)

<400> 7
 tgtacactcc gacattcagc tgacctcagtc tccagcaatc atgtctgcattt cttccaggggaa 60
 gaagggtcacc atgaccttgca gagccagttc aagtgttaat tacatgaactt ggtaccagca 120
 gaagtcaggc acctccccca aaagatggat ttatgacaca tccaaagtgg cttctggagt 180
 cccttatcgcc ttcatgtggca gtgggtctgg gacctcatac tctctcacaa tcagcagcat 240
 ggaggctgaa gatgctgcca cttattactg ccaacagtgg agtagtaacc cgctcacgtt 300

11

cggtgctggg accaagctgg agctgaaagg tggtgtggt tctggcggcg gcggctccgg	360
tggtgtggt tctgatatca aactgcagca gtcaggggct gaactggcaa gacctggggc	420
ctcagtgaag atgtcctgca agacttctgg ctacaccctt actaggtaca cgatgcactg	480
ggtaaaaacag aggccctggac agggcttgga atggattgga tacattaatc ctagccgtgg	540
ttataactaat tacaatcaga agttcaagga caaggccaca ttgactacag acaaattcctc	600
cagcacagcc tacatgcaac tgagcagcct gacatctgag gactctgcag tcttattactg	660
tgcaagatat tatgatgatc attactgcct tgactactgg ggccaaggca ccactctcac	720
agtctcctca tccggaggtg gtggatccc ggtgcagctg cagcagtctg gggctgagct	780
ggtgaggcct gggtcctcag tgaagatttc ctgcaaggct tctggctatg cattcagtag	840
ctactggatg aactgggtga agcagaggcc tggacagggc cttgagtgga ttggacagat	900
ttggcctgga gatggtgata ctaactacaa tggaaagttc aagggtaaag ccactctgac	960
tgcagacgaa tcctccagca cagcctacat gcaactcagc agcctagcat ctgaggactc	1020
tgcggtctat ttctgtgcaa gacgggagac tacgacggta ggccgttatt actatgctat	1080
ggactactgg ggccaaggga ccacggtcac cgtctcctcc ggtgggtggt gttctggcgg	1140
cggcggctcc ggtgggtggt gttctgatat ccagctgacc cagtctccag cttctttggc	1200
tgtgtctcta gggcagaggg ccaccatctc ctgcaaggcc agccaaagtg ttgattatga	1260
tggtgatagt tatttgaact ggtaccaaca gattccagga cagccaccca aactcctcat	1320
ctatgatgca tccaatctag tttctggat cccacccagg ttttagtgca gtgggtctgg	1380
gacagacttc accctcaaca tccatcctgt ggagaaggtg gatgctgcaa cctatcactg	1440
tcagcaaagt actgaggatc cgtggacgtt cggggaggg accaagctcg agatcaaatc	1500
cgggcatcat caccatcatc attgagtcga c	1531

<210> 8

<211> 504

<212> PRT

<213> artificial sequence

<220>

<223> Translation of a CD3 VL/VH x CD19 VH/VL (mature protein w/o Leader)

<400> 8

Asp Ile Gln Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly			
1	5	10	15

Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Met		
20	25	30

Asn Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr
35 40 45

Asp Thr Ser Lys Val Ala Ser Gly Val Pro Tyr Arg Phe Ser Gly Ser
50 55 60

Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu
65 70 75 80

Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Leu Thr
85 90 95

Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Gly Gly Gly Ser Gly
100 105 110

Gly Gly Ser Gly Gly Gly Ser Asp Ile Lys Leu Gln Gln Ser
115 120 125

Gly Ala Glu Leu Ala Arg Pro Gly Ala Ser Val Lys Met Ser Cys Lys
130 135 140

Thr Ser Gly Tyr Thr Phe Thr Arg Tyr Thr Met His Trp Val Lys Gln
145 150 155 160

Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Tyr Ile Asn Pro Ser Arg
165 170 175

Gly Tyr Thr Asn Tyr Asn Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr
180 185 190

Thr Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr
195 200 205

Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Tyr Tyr Asp Asp His
210 215 220

Tyr Cys Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser
225 230 235 240

Ser Gly Gly Gly Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu
245 250 255

Leu Val Arg Pro Gly Ser Ser Val Lys Ile Ser Cys Lys Ala Ser Gly
260 265 270

Tyr Ala Phe Ser Ser Tyr Trp Met Asn Trp Val Lys Gln Arg Pro Gly
275 280 285

Gln Gly Leu Glu Trp Ile Gly Gln Ile Trp Pro Gly Asp Gly Asp Thr
290 295 300

Asn Tyr Asn Gly Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Glu

305	310	¹³ 315	320
Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Ala Ser Glu Asp			
	325	330	335
Ser Ala Val Tyr Phe Cys Ala Arg Arg Glu Thr Thr Thr Val Gly Arg			
	340	345	350
Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val			
	355	360	365
Ser Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Gly			
	370	375	380
Ser Asp Ile Gln Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu			
	385	390	395
Gly Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr			
	405	410	415
Asp Gly Asp Ser Tyr Leu Asn Trp Tyr Gln Gln Ile Pro Gly Gln Pro			
	420	425	430
Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Val Ser Gly Ile Pro			
	435	440	445
Pro Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile			
	450	455	460
His Pro Val Glu Lys Val Asp Ala Ala Thr Tyr His Cys Gln Gln Ser			
	465	470	475
Thr Glu Asp Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys			
	485	490	495
Ser Gly His His His His His			
	500		

<210> 9

<211> 1531

<212> DNA

<213> artificial sequence

<220>

<223> Nucleotide sequence of CD3 VH/VL x CD19 VH/VL (BsrG I to sal I)

<400> 9

tgtacactcc gatatcaaac tgcagcagtc agggctgaa ctggcaagac ctggggcctc	60
agtgaagatg tcctgcaaga cttctggcta caccttact aggtacacga tgcactgggt	120

aaaacagagg cctggacagg gtctggaatg gattggatac attaattccta gccgtggta	180
tactaattac aatcagaagt tcaaggacaa ggccacattg actacagaca aatcctccag	240
cacagcctac atgcaactga gcagcctgac atctgaggac tctgcagtct attactgtgc	300
aagatattat gatgatcatt actgccttga ctactggggc caaggcacca ctctcacagt	360
ctcctcaggt ggtggtggtt ctggcggcgg cggtcccggt ggtggtggtt ctgacattca	420
gctgaccagg tctccagcaa tcatgtctgc atctccaggg gagaaggtaa ccatgacactg	480
cagagccagt tcaagtgtaa gttacatgaa ctggtaccag cagaagtcag gcacccccc	540
caaaagatgg atttatgaca catccaaagt ggcttctgga gtcccttatac gcttcagtgg	600
cagtgggtct gggacctcat actctctcac aatcagcagc atggaggctg aagatgctgc	660
cacttattac tgccaacagt ggagtagtaa cccgctcacg ttccggtgctg ggaccaagct	720
ggagctgaaa tccggaggtg gtggatccca ggtgcagctg cagcagtctg gggctgagct	780
ggtgaggcct gggcctcag tgaagatttc ctgcaaggct tctggctatg cattcagtag	840
ctactggatg aactgggtga agcagaggcc tggacagggc cttgagtgga ttggacagat	900
ttggcctgga gatggtgata ctaactacaa tggaaagttc aaggtaaag ccactctgac	960
tgcagaccaa tcctccagca cagcctacat gcaactcagc agcctagcat ctgaggactc	1020
tgcggcttat ttctgtcaa gacggagac tacgacggta ggccgttatt actatgttat	1080
ggactactgg ggccaaggga ccacggtcac cgtctcctcc ggtggtggtg gttctggcgg	1140
cgccggctcc ggtggtggtg gttctgatat ccagctgacc cagtctccag cttctttggc	1200
tgtgtctcta gggcagaggg ccaccatctc ctgcaaggcc agccaaagtg ttgattatga	1260
tggtgatagt tatttgaact ggtaccaaca gattccagga cagccaccca aactcctcat	1320
ctatgtgca tccaatctag tttctggat cccacccagg ttttagtgca gtgggtctgg	1380
gacagacttc accctcaaca tccatcctgt ggagaagggtg gatgctgcaa cctatcactg	1440
tcagcaaagt actgaggatc cgtggacgtt cggtggaggg accaagctcg agatcaaatc	1500
cgggcatcat caccatcatc attgagtcga c	1531

<210> 10

<211> 504

<212> PRT

<213> artificial sequence

<220>

<223> Translation of CD3 VH/VL x CD19 VH/VL (mature protein w/o Leader)

<400> 10

Asp Ile Lys Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala
1 5 10 15

15

Ser Val Lys Met Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Arg Tyr
20 25 30

Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Phe
50 55 60

Lys Asp Lys Ala Thr Leu Thr Thr Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr Trp Gly Gln Gly
100 105 110

Thr Thr Leu Thr Val Ser Ser Gly Gly Gly Ser Gly Gly Gly
115 120 125

Ser Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ala Ile
130 135 140

Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser
145 150 155 160

Ser Ser Val Ser Tyr Met Asn Trp Tyr Gln Gln Lys Ser Gly Thr Ser
165 170 175

Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Val Ala Ser Gly Val Pro
180 185 190

Tyr Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile
195 200 205

Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp
210 215 220

Ser Ser Asn Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
225 230 235 240

Ser Gly Gly Gly Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu
245 250 255

Leu Val Arg Pro Gly Ser Ser Val Lys Ile Ser Cys Lys Ala Ser Gly
260 265 270

Tyr Ala Phe Ser Ser Tyr Trp Met Asn Trp Val Lys Gln Arg Pro Gly
275 280 285

Gln Gly Leu Glu Trp Ile Gly Gln Ile Trp Pro Gly Asp Gly Asp Thr¹⁶
290 295 300

Asn Tyr Asn Gly Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Glu
305 310 315 320

Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Ala Ser Glu Asp
325 330 335

Ser Ala Val Tyr Phe Cys Ala Arg Arg Glu Thr Thr Thr Val Gly Arg
340 345 350

Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val
355 360 365

Ser Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly
370 375 380

Ser Asp Ile Gln Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu
385 390 395 400

Gly Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr
405 410 415

Asp Gly Asp Ser Tyr Leu Asn Trp Tyr Gln Gln Ile Pro Gly Gln Pro
420 425 430

Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Val Ser Gly Ile Pro
435 440 445

Pro Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile
450 455 460

His Pro Val Glu Lys Val Asp Ala Ala Thr Tyr His Cys Gln Gln Ser
465 470 475 480

Thr Glu Asp Pro Trp Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys
485 490 495

Ser Gly His His His His His
500

<210> 11

<211> 1528

<212> DNA

<213> artificial sequence

<220>

<223> Nucleotide sequence of CD3 VL/VH x CD19 VL/VH (BsrG I to Sal I)

<400> 11
tgtacactcc gacattcagc tgacccagtc tccagcaatc atgtctgcat ctccagggg 60
gaaggtcacc atgacacctgca gagccagttc aagtgttaat tacatgaact ggtaccagca 120
gaagtcaggc acctccccca aaagatggat ttatgacaca tccaaagtgg cttctggagt 180
cccttatcg 6 cttcagtgca gtgggtctgg gacctcatac tctctcacaa tcagcagcat 240
ggaggctgaa gatgctgcc 6 a cttattactg ccaacagtgg agtagtaacc cgctcacg 300
cggtgctggg accaagctgg agctgaaagg tgggtgggt tctggcggcg gcggctccgg 360
tgggtgggt tctgatata 6 ca aactgcagca gtcaggggct gaactggcaa gacctggggc 420
ctcagtgaag atgtcctgca agacttctgg ctacacc 6 ttt actaggtaca cgatgcactg 480
ggtaaaaacag aggctggac agggtctgg 6 a atggattgga tacattaatc cttagccgtgg 540
ttatacta 6 at tacaatcaga agttcaagga caaggccaca ttgactacag acaaattcctc 600
cagcacagcc tacatgcaac tgagcagc 6 ct gacatctgag gactctgcag tctattactg 660
tgcaagat 6 at tatgatgatc attactgcct tgactactgg ggccaaggca ccactctcac 720
agtctcctca tccggaggtg gtggatccga tatccagctg acccagtctc cagttcttt 780
ggctgtgtct 6 ctagggcaga gggccaccat ctcctgcaag gccagccaaa gtgttgatta 840
tgatggtgat agttatttga actgg 6 tacca acagattcca ggacagccac ccaaactcct 900
catctatgat gcatccaatc tagttctgg gatcccaccc agtttagtgc 6 gca gttgggtc 960
tggacagac ttcaccctca acatccatcc tgtggagaag gtggatgctg caacctatca 1020
ctgtcagcaa agtactgagg atccgtggac gttcggtgg 6 gggaccaagc tcgagatcaa 1080
agg 6 tgggtgg 6 gtgtctggcg gcggcggctc cgggtgggtt ggttctcagg tgcagctgca 1140
gcagtctggg gctgagctgg tgaggcctgg gtcctcagtg aagatttcct gcaaggcttc 1200
tggctatgca ttcagtagct actggatgaa ctgggtgaag cagaggcctg gacagggtct 1260
tgagtggatt ggacagattt ggcctggaga tgg 6 tgatact aactacaatg gaaagttcaa 1320
ggtaaagcc actctgactg cagacgaatc ctccagcaca gcctacatgc aactcagcag 1380
cctagcatct gaggactctg cgg 6 tctattt ctgtgcaaga cgggagacta cgacggtagg 1440
ccgttattac tatgctatgg actactggg ccaaggacc acggtcaccg tctcctccgg 1500
gcatcatcac catcatcatt gagtcgac 1528

<210> 12

<211> 503

<212> PRT

<213> artificial sequence

<220>

<223> Translation of CD3 VL/VH x CD19 VL/VH (mature protein w/o Leader
)

<400> 12

Asp Ile Gln Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly
1 5 10 15

Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Met
20 25 30

Asn Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr
35 40 45

Asp Thr Ser Lys Val Ala Ser Gly Val Pro Tyr Arg Phe Ser Gly Ser
50 55 60

Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu
65 70 75 80

Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Leu Thr
85 90 95

Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Gly Gly Gly Ser Gly
100 105 110

Gly Gly Gly Ser Gly Gly Gly Ser Asp Ile Lys Leu Gln Gln Ser
115 120 125

Gly Ala Glu Leu Ala Arg Pro Gly Ala Ser Val Lys Met Ser Cys Lys
130 135 140

Thr Ser Gly Tyr Thr Phe Thr Arg Tyr Thr Met His Trp Val Lys Gln
145 150 155 160

Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Tyr Ile Asn Pro Ser Arg
165 170 175

Gly Tyr Thr Asn Tyr Asn Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr
180 185 190

Thr Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr
195 200 205

Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Tyr Tyr Asp Asp His
210 215 220

Tyr Cys Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser
225 230 235 240

Ser Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ala Ser
245 250 255

Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser
260 265 270

Gln Ser Val Asp Tyr Asp Gly Asp Ser Tyr Leu Asn Trp Tyr Gln Gln
275 280 285

Ile Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu
290 295 300

Val Ser Gly Ile Pro Pro Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
305 310 315 320

Phe Thr Leu Asn Ile His Pro Val Glu Lys Val Asp Ala Ala Thr Tyr
325 330 335

His Cys Gln Gln Ser Thr Glu Asp Pro Trp Thr Phe Gly Gly Thr
340 345 350

Lys Leu Glu Ile Lys Gly Gly Gly Ser Gly Gly Gly Ser Gly
355 360 365

Gly Gly Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val
370 375 380

Arg Pro Gly Ser Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala
385 390 395 400

Phe Ser Ser Tyr Trp Met Asn Trp Val Lys Gln Arg Pro Gly Gln Gly
405 410 415

Leu Glu Trp Ile Gly Gln Ile Trp Pro Gly Asp Gly Asp Thr Asn Tyr
420 425 430

Asn Gly Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Glu Ser Ser
435 440 445

Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala
450 455 460

Val Tyr Phe Cys Ala Arg Arg Glu Thr Thr Val Gly Arg Tyr Tyr
465 470 475 480

Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
485 490 495

Gly His His His His His His
500

<210> 13

<211> 1528

<212> DNA

<213> artificial sequence

<220>

<223> Nucleotide sequence of CD3 VH/VL x CD19 VL/VH (BsrG I to Sal I)

<400> 13

tgtacactcc	gatataaaac	tgcagcagtc	aggggctgaa	ctggcaagac	ctggggcctc	60
agtgaagatg	tcctgcaaga	cttctggcta	cacccttact	aggtacacga	tgcactgggt	120
aaaacagagg	cctggacagg	gtctggaatg	gattggatac	attaatccta	gccgtggta	180
tactaattac	aatcagaagt	tcaaggacaa	ggccacattt	actacagaca	aatcctccag	240
cacagcctac	atgcaactga	gcagcctgac	atctgaggac	tctgcagtct	attactgtgc	300
aagatattat	gatgatcatt	actgccttga	ctactggggc	caaggcacca	ctctcacagt	360
ctcctcaggt	ggtgggtggtt	ctggcgccgg	cggctccgg	ggtgggtggtt	ctgacattca	420
gctgacccag	tctccagcaa	tcatgtctgc	atctccaggg	gagaaggta	ccatgacactg	480
cagagccagt	tcaagtgtaa	gttacatgaa	ctggtaccag	cagaagtcag	gcacccccc	540
caaaagatgg	atttatgaca	catccaaagt	ggcttctgga	gtcccttatac	gcttcagtg	600
cacttattac	tgccaacagt	ggagtagtaa	cccgcacag	ttcggtgctg	ggaccaagct	720
ggagctgaaa	tccggaggtg	gtggatccga	tatccagctg	acccagtctc	cagttcttt	780
ggctgtgtct	ctagggcaga	ggccaccat	ctcctgcaag	gccagccaaa	gtgttgatta	840
tgatggtgat	agttatttga	actggtagcca	acagattcca	ggacagccac	ccaaactcct	900
catctatgat	gcatccaaatc	tagttctgg	gatcccaccc	agtttagtg	gcagtgggtc	960
tggacagac	ttcacccctca	acatccatcc	tgtggagaag	gtggatgctg	caacatatca	1020
ctgtcagcaa	agtactgagg	atccgtggac	gttcggtgga	gggaccaagc	tcgagatcaa	1080
aggtgggtgt	ggttctggcg	gcggcggttc	cgggtgggt	ggttctcagg	tgcagctgca	1140
gcagtctggg	gctgagctgg	tgaggcctgg	gtcctcagtg	aagatttcct	gcaaggcttc	1200
tggctatgca	ttcagtagct	actggatgaa	ctgggtgaag	cagaggcctg	gacagggtct	1260
tgagtggatt	ggacagattt	ggcctggaga	tggtgatact	aactacaatg	gaaagttcaa	1320
gggtaaagcc	actctgactg	cagacgaatc	ctccagcaca	gcctacatgc	aactcagcag	1380
cctagcatct	gaggactctg	cggcttattt	ctgtgcaaga	cgggagacta	cgacggtagg	1440
ccgttattac	tatgctatgg	actactgggg	ccaaaggacc	acggtcaccg	tctcctccgg	1500
gcatcatcac	catcatcatt	gagtcgac				1528

<210> 14

<211> 503

<212> PRT

<213> artificial sequence

<220>

<223> Translation of CD3 VH/VL x CD19 VL/VH (mature protein w/o Leader)

<400> 14

Asp Ile Lys Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala
1 5 10 15

Ser Val Lys Met Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Arg Tyr
20 25 30

Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Phe
50 55 60

Lys Asp Lys Ala Thr Leu Thr Thr Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr Trp Gly Gln Gly
100 105 110

Thr Thr Leu Thr Val Ser Ser Gly Gly Gly Ser Gly Gly Gly Gly
115 120 125

Ser Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ala Ile
130 135 140

Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser
145 150 155 160

Ser Ser Val Ser Tyr Met Asn Trp Tyr Gln Gln Lys Ser Gly Thr Ser
165 170 175

Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Val Ala Ser Gly Val Pro
180 185 190

Tyr Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile
195 200 205

Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp
210 215 220

Ser Ser Asn Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
225 230 235 240

Ser Gly Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ala Ser
245 250 255

Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser
260 265 270

Gln Ser Val Asp Tyr Asp Gly Asp Ser Tyr Leu Asn Trp Tyr Gln Gln
275 280 285

Ile Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu
290 295 300

Val Ser Gly Ile Pro Pro Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
305 310 315 320

Phe Thr Leu Asn Ile His Pro Val Glu Lys Val Asp Ala Ala Thr Tyr
325 330 335

His Cys Gln Gln Ser Thr Glu Asp Pro Trp Thr Phe Gly Gly Thr
340 345 350

Lys Leu Glu Ile Lys Gly Gly Ser Gly Gly Gly Ser Gly
355 360 365

Gly Gly Gly Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val
370 375 380

Arg Pro Gly Ser Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala
385 390 395 400

Phe Ser Ser Tyr Trp Met Asn Trp Val Lys Gln Arg Pro Gly Gln Gly
405 410 415

Leu Glu Trp Ile Gly Gln Ile Trp Pro Gly Asp Gly Asp Thr Asn Tyr
420 425 430

Asn Gly Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Glu Ser Ser
435 440 445

Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala
450 455 460

Val Tyr Phe Cys Ala Arg Arg Glu Thr Thr Val Gly Arg Tyr Tyr
465 470 475 480

Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
485 490 495

Gly His His His His His
500

23

<211> 38

<212> DNA

<213> artificial sequence

<220>

<223> 5' VLL2KBspEIGS

<400> 15

cttccggagg tggtggtatcc gacattcagc tgacccag

38

<210> 16

<211> 25

<212> DNA

<213> artificial sequence

<220>

<223> 3' VHL2KBspEI (C-terminal)

<400> 16

cctccggagg agactgtgag agtgg

25

<210> 17

<211> 38

<212> DNA

<213> artificial sequence

<220>

<223> 5' VHCD19BspEIGS

<400> 17

cttccggagg tggtggtatcc caggtgcagc tgcagcag

38

<210> 18

<211> 25

<212> DNA

<213> artificial sequence

<220>

<223> 3' VLCM19BspEI (C-terminal)

<400> 18

cctccggatt tcatctcgag cttgg

25

<210> 19
<211> 35
<212> DNA
<213> artificial sequence

<220>
<223> 5' VLCD19BspEIGS
<400> 19
cttccggagg tggatcc gatatccagg tgacc

35

<210> 20
<211> 31
<212> DNA
<213> artificial sequence

<220>
<223> 5' VHL2KBsrGI
<400> 20
agggtacac tccgatatca aactgcagca g

31

<210> 21
<211> 50
<212> DNA
<213> artificial sequence

<220>
<223> 3' VHL2KGS15
<400> 21
ggagccgccc ccgcagaac caccaccacc tgaggagact gtgagagtgg

50

<210> 22
<211> 53
<212> DNA
<213> artificial sequence

<220>
<223> 5' VLL2KGS15

25

<400> 22
ggcggcggcg gctccgggtgg tggtggttct gacattcagc tgaccaggc tcc 53

<210> 23

<211> 25

<212> DNA

<213> artificial sequence

<220>

<223> 3' VLL2KBspEI

<400> 23
aatccggatt tcagctccag cttgg 25

<210> 24

<211> 31

<212> DNA

<213> artificial sequence

<220>

<223> 5' VHCD19BsrGI

<400> 24
aggtgtacac tcccagggtgc agctgcagca g 31

<210> 25

<211> 50

<212> DNA

<213> artificial sequence

<220>

<223> 3' VHCD19GS15

<400> 25
ggagccgccc g cgcgcagaac caccaccacc ggaggagacg gtgaccgtgg 50

<210> 26

<211> 53

<212> DNA

<213> artificial sequence

26

<220>

<223> 5' VLCD19GS15

<400> 26

ggcggcgccg gctccgggtgg tggtggttct gatatccagc tgaccaggc tcc 53

<210> 27

<211> 25

<212> DNA

<213> artificial sequence

<220>

<223> 3' VLCD19BspEI

<400> 27

aatccggatt tggatctcgag cttgg 25

<210> 28

<211> 39

<212> DNA

<213> artificial sequence

<220>

<223> 3' VH BspEI

<400> 28

aatccggagg agacggtgac cgtggccct tggccccag 39

<210> 29

<211> 1587

<212> DNA

<213> artificial sequence

<220>

<223> Nucleotide sequence of CD19 VL/VH x CD3 VH/VL

<400> 29

gaattccacc atgggatgga gctgttatcat cctcttcttg gtagcaacag ctacagggtgt 60

acactccgat atccagctga cccagtctcc agcttcttgc gctgtgtctc tagggcagag 120

ggccaccatc tcctgcaagg ccagccaaag tggattat gatggtgata gttatttcaa 180

ctggtaaaaa cagattccag gacagccacc caaactcctc atctatgtatg catccaatct 240

agtttctggg atcccaccca ggtagtgg cagtgggtct gggacagact tcaccctcaa 300

27

catccatcct	gtggagaagg	tggatgctgc	aacctatcac	tgtcagcaaa	gtactgagga	360
tccgtggacg	ttcggtggag	ggaccaagct	cgagatcaaa	ggtggtggtg	gttctggcgg	420
cggcggctcc	ggtggtggtg	gttctcaggt	gcagctgcag	cagtctgggg	ctgagctggt	480
gaggcctggg	tcctcagtga	agatttcctg	caaggcttct	ggctatgcat	tca tagtagcta	540
ctggatgaac	tgggtgaagc	agaggcctgg	acagggtctt	gagtggattg	gacagatttg	600
gcctggagat	ggtgatacta	actacaatgg	aaagttcaag	ggtaaagcca	ctctgactgc	660
agacgaatcc	tccagcacag	cctacatgca	actcagcagc	ctagcatctg	aggactctgc	720
ggtctatttc	tgtgcaagac	gggagactac	gacggtaggc	cgttattact	atgctatgga	780
ctactggggc	caagggacca	cggtcaccgt	ctcctccgga	ggtggtggat	ccgatatcaa	840
actgcagcag	tcaggggctg	aactggcaag	acctggggcc	tcagtgaaga	tgtcctgcaa	900
gacttctggc	tacacctta	ctaggtacac	gatcactgg	gtaaaacaga	ggcctggaca	960
gggtctggaa	tggattggat	acattaatcc	tagccgtgg	tatactaatt	acaatcagaa	1020
gttcaaggac	aaggccacat	tgactacaga	caaattctcc	agcacagcct	acatgcaact	1080
gagcagcctg	acatctgagg	actctgcagt	ctattactgt	gcaagatatt	atgatgatca	1140
ttactgcctt	gactactggg	gccaaaggcac	cactctcaca	gtctcctcag	tcgaaggtgg	1200
aagtggaggt	tctggtggaa	gtggaggttc	aggtggagtc	gacgacattc	agctgaccca	1260
gtctccagca	atcatgtctg	catctccagg	ggagaaggtc	accatgaccc	gcagagccag	1320
ttcaagtgt	agttacatga	actgg tacca	gcagaagtca	ggcacctccc	ccaaaagatg	1380
gatttatgac	acatccaaag	tggcttctgg	agtcccttat	cgcttcagtg	gcagtgggtc	1440
tgggacctca	tactctctca	caatcagcag	catggaggct	gaagatgctg	ccacttatta	1500
ctgccaacag	tggagtagta	acccgctcac	gttcggtgct	gggaccaagc	tggagctgaa	1560
acatcatcac	catcatcatt	agtcgac				1587

<210> 30

<211> 504

<212> PRT

<213> artificial sequence

<220>

<223> Translation of CD19 VL/VH x CD3 VH/VL

<400> 30

Asp	Ile	Gln	Leu	Thr	Gln	Ser	Pro	Ala	Ser	Leu	Ala	Val	Ser	Leu	Gly
1				5				10					15		

Gln	Arg	Ala	Thr	Ile	Ser	Cys	Lys	Ala	Ser	Gln	Ser	Val	Asp	Tyr	Asp
				20				25				30			

Gly Asp Ser Tyr Leu Asn Trp Tyr Gln ²⁸ Gln Ile Pro Gly Gln Pro Pro
35 40 45

Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Val Ser Gly Ile Pro Pro
50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His
65 70 75 80

Pro Val Glu Lys Val Asp Ala Ala Thr Tyr His Cys Gln Gln Ser Thr
85 90 95

Glu Asp Pro Trp Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys Gly
100 105 110

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gln Val
115 120 125

Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ser Ser Val
130 135 140

Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Tyr Trp Met
145 150 155 160

Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Gln
165 170 175

Ile Trp Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys Gly
180 185 190

Lys Ala Thr Leu Thr Ala Asp Glu Ser Ser Ser Thr Ala Tyr Met Gln
195 200 205

Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg
210 215 220

Arg Glu Thr Thr Thr Val Gly Arg Tyr Tyr Tyr Ala Met Asp Tyr Trp
225 230 235 240

Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Asp
245 250 255

Ile Lys Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala Ser
260 265 270

Val Lys Met Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Arg Tyr Thr
275 280 285

Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly
290 295 300

Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Phe Lys

305 310 . ²⁹
 . . ₃₁₅ . 320

Asp Lys Ala Thr Leu Thr Thr Asp Lys Ser Ser Ser Thr Ala Tyr Met
325 330 335

Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala
340 345 350

Arg Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr Trp Gly Gln Gly Thr
355 360 365

Thr Leu Thr Val Ser Ser Val Glu Gly Gly Ser Gly Gly Ser Gly Gly
370 375 380

Ser Gly Gly Ser Gly Gly Val Asp Asp Ile Gln Leu Thr Gln Ser Pro
385 . 390 . 395 . 400

Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg
405 410 415

Thr Ser Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Val Ala Ser Gly
435 440 445

Val Pro Tyr Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu
450 455 460

Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln
465 470 475 480

Gln Trp Ser Ser Asn Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu
485 490 495 500 505 510 515 520 525 530 535 540 545

Leu Lys His His His His His His
500

<210> 31

-211- 35

-212- RNA

<213> artificial sequence

1270

<223> 5'VII.2KB-65

-100- 31

agggtgtacac tccgacattc agctgaccca gtctc

30

<210> 32

<211> 50

<212> DNA

<213> artificial sequence

<220>

<223> 3'VLL2KGS15

<400> 32

ggagccgccc

50

ccgcagaac caccaccacc tttcagctcc agcttggtcc

<210> 33

<211> 53

<212> DNA

<213> artificial sequence

<220>

<223> 5'VHL2KGS15

<400> 33

ggcggcggcg

53

gctccggtgg tggtggttct gatataaac tgcagcagtc agg

<210> 34

<211> 30

<212> DNA

<213> artificial sequence

<220>

<223> 3'VHL2KBspEI

<400> 34

aatccggatg aggagactgt gagagtggtg

30

<210> 35

<211> 25

<212> DNA

<213> artificial sequence

<220>

<223> 3'VHCD19BspEI (C-terminal)

<400> 35

31

cctccggagg agacggtgac cgtgg

25

<210> 36

<211> 73

<212> DNA

<213> artificial sequence

<220>

<223> CTI Polylinker

<400> 36

tctagaattc ttcgaatccg gaggtggtgg atccgatatac cccgggcatac atcaccatca

60

tcattgagtc gac

73

<210> 37

<211> 36

<212> DNA

<213> artificial sequence

<220>

<223> 5' L1

<400> 37

gaagcacgcg tagatatckt gmtcaccaa wctcca

36

<210> 38

<211> 30

<212> DNA

<213> artificial sequence

<220>

<223> 3' K

<400> 38

gaagatggat ccagcggccg cagcatcagc

30

<210> 39

<211> 33

<212> DNA

<213> artificial sequence

32

<220>

<223> 5' H1

<400> 39

cagccggcca tggcgccagg scagctgcag sag

33

<210> 40

<211> 39

<212> DNA

<213> artificial sequence

<220>

<223> 3' G

<400> 40

accaggggcc agtggataga caagcttggg tgtcgttt

39

<210> 41

<211> 37

<212> DNA

<213> artificial sequence

<220>

<223> 5' VLB5RRV

<400> 41

aggtgtacac tccgatatcc agctgaccca gtctcca

37

<210> 42

<211> 51

<212> DNA

<213> artificial sequence

<220>

<223> 3' VLGS15

<400> 42

ggagccgccc ccgccagaac caccaccacc tttgatctcg agcttggtcc c

51

<210> 43

<211> 53

<212> DNA

<213> artificial sequence

<220>

<223> 5' VHGS15

<400> 43

ggcggccggcg gctccgggtgg tggtggttct caggtsmarc tgcagsagtc wgg

53

<210> 44

<211> 750

<212> DNA

<213> artificial sequence

<220>

<223> CD19 VH/VL nuc

<400> 44

caggtgcagc tgcagcagtc tggggctgag ctgggtgaggc ctgggtcctc agtgaagatt

60

tcctgcaagg cttctggcta tgcattcagt agctactgga tgaactgggt gaagcagagg

120

cctggacagg gtcttgagtg gattggacag atttggcctg gagatggtga tactaactac

180

aatggaaagt tcaaggtaa agccactctg actgcagacg aatcctccag cacagcctac

240

atgcaactca gcagcctagc atctgaggac tctgcggctc atttctgtgc aagacggag

300

actacgacgg taggccgtta ttactatgct atggactact gggccaagg gaccacggc

360

accgtctcct ccgggtgggtgg tggttctggc ggccggcggct ccgggtgggtgg tggttctgtat

420

atccagctga cccagtcctcc agcttctttg gctgtgtctc tagggcagag ggccaccatc

480

tcctgcaagg ccagccaaag tggattat gatgggtata gttatttcaa ctggtaaaaa

540

cagattccag gacagccacc caaactcctc atctatgtatg catccaatct agtttctggg

600

atccccaccca ggttagtgg cagtgggtct gggacagact tcaccctcaa catccatcct

660

gtggagaagg tggatgctgc aacctatcac tgtcagcaaa gtactgagga tccgtggacg

720

ttcgggtggag ggaccaagct cgagatcaaa

750

<210> 45

<211> 250

<212> PRT

<213> artificial sequence

<220>

<223> CD19 VH/VL aa

<400> 45

34

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ser
1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Tyr
20 25 30

Trp Met Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Gln Ile Trp Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe
50 55 60

Lys Gly Lys Ala Thr Leu Thr Ala Asp Glu Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met Gln Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Phe Cys
85 90 95

Ala Arg Arg Glu Thr Thr Val Gly Arg Tyr Tyr Tyr Ala Met Asp
100 105 110

Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly
115 120 125

Ser Gly Gly Gly Ser Gly Gly Ser Asp Ile Gln Leu Thr
130 135 140

Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile
145 150 155 160

Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp Gly Asp Ser Tyr Leu
165 170 175

Asn Trp Tyr Gln Gln Ile Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr
180 185 190

Asp Ala Ser Asn Leu Val Ser Gly Ile Pro Pro Arg Phe Ser Gly Ser
195 200 205

Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Lys Val
210 215 220

Asp Ala Ala Thr Tyr His Cys Gln Gln Ser Thr Glu Asp Pro Trp Thr
225 230 235 240

Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
245 250

<210> 46

<211> 729

<212> DNA

<213> artificial sequence

<220>

<223> CD3 VH/VL nuc

<400> 46
 gatatacaaac tgcagcagtc aggggctgaa ctggcaagac ctggggcctc agtgaagatg 60
 tcctgcaaga cttctggcta cacctttact aggtacacga tgcactgggt aaaacagagg 120
 cctggacagg gtctggaatg gattggatac attaatccta gccgtggta tactaattac 180
 aatcagaagt tcaaggacaa ggccacattg actacagaca aatcctccag cacagcctac 240
 atgcaactga gcagcctgac atctgaggac tctgcagtct attactgtgc aagatattat 300
 gatgatcatt actgccttga ctactggggc caaggcacca ctctcacagt ctcctcagtc 360
 gaagggtggaa gtggaggttc tggtggaagt ggaggtttagt gtggagtcga cgacattcag 420
 ctgaccagg ctccagcaat catgtctgca tctccaggg agaaggtcac catgacctgc 480
 agagccagtt caagtgttaag ttacatgaac tggtaccagc agaagtcagg cacctcccc 540
 aaaagatgga tttatgacac atccaaagtg gcttctggag tcccttatcg cttcagtggc 600
 agtgggtctg ggacctcata ctctctcaca atcagcagca tggaggctga agatgctgcc 660
 acttattact gccaacagtg gagtagtaac ccgctcacgt tcggtgctgg gaccaagctg 720
 gagctgaaa 729

<210> 47

<211> 243

<212> PRT

<213> artificial sequence

<220>

<223> CD3 VH/VL aa

<400> 47

Asp Ile Lys Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala
 1 5 10 15

Ser Val Lys Met Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Arg Tyr
 20 25 30

Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45

Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Phe
 50 55 60

Lys Asp Lys Ala Thr Leu Thr Thr Asp Lys³⁶ Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr Trp Gly Gln Gly
100 105 110

Gly Ser Gly Gly Ser Gly Gly Val Asp Asp Ile Gln Leu Thr Gln Ser
130 135 140

Arg Ala Ser Ser Ser Val Ser Tyr Met Asn Trp Tyr Gln Gln Lys Ser
165 170 175

Gly Val Pro Tyr Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser
195 200 205 .

Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys
210 215 220

Gln Gln Trp Ser Ser Asn Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu
225 230 235 240

flu-leu-lys

<210> 48

<211> 750

<212> DNA

<220>

CDI

<400> 48

gatccggc tgaccaggc ccagcccccc cggcggtggc ccccaaaaaa gaaaaaaatcc

caacagattc caggacagcc acccaaactc ctcatctatg atgcatccaa tctagttct

37

gggatccac ccaggttag tggcagtgg tctggacag acttcaccct caacatccat 240
 cctgtggaga aggtggatgc tgcaacctat cactgtcagc aaagtactga ggatccgtgg 300
 acgttcggtg gagggaccaa gctcgagatc aaagggtggtg gtggttctgg cggcggcggc 360
 tccgggtggtg gtggttctca ggtcagctg cagcagtctg gggctgagct ggtgaggcct 420
 gggtcctcag tgaagatttc ctgcaaggct tctggctatg cattcagtag ctactggatg 480
 aactgggtga agcagaggcc tggacagggc tttgagtgga ttggacagat ttggcctgga 540
 gatggtgata ctaactacaa tggaaagtcc aaggtaaag ccactctgac tgcagacgaa 600
 tcctccagca cagcctacat gcaactcagc agcctagcat ctgaggactc tgcggcttat 660
 ttctgtgcaa gacgggagac tacgacggta ggccgttatt actatgctat ggactactgg 720
 ggccaaggga ccacggtcac cgtctcctcc 750

<210> 49

<211> 250

<212> PRT

<213> artificial sequence

<220>

<223> CD19 VL/VH aa

<400> 49

Asp	Ile	Gln	Leu	Thr	Gln	Ser	Pro	Ala	Ser	Leu	Ala	Val	Ser	Leu	Gly
1				5				10					15		

Gln	Arg	Ala	Thr	Ile	Ser	Cys	Lys	Ala	Ser	Gln	Ser	Val	Asp	Tyr	Asp
				20			25					30			

Gly	Asp	Ser	Tyr	Leu	Asn	Trp	Tyr	Gln	Gln	Ile	Pro	Gly	Gln	Pro	Pro
				35			40				45				

Lys	Leu	Leu	Ile	Tyr	Asp	Ala	Ser	Asn	Leu	Val	Ser	Gly	Ile	Pro	Pro
				50			55				60				

Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Asn	Ile	His
65				70				75				80			

Pro	Val	Glu	Lys	Val	Asp	Ala	Ala	Thr	Tyr	His	Cys	Gln	Gln	Ser	Thr
				85				90				95			

Glu	Asp	Pro	Trp	Thr	Phe	Gly	Gly	Gly	Thr	Lys	Leu	Glu	Ile	Lys	Gly
				100			105				110				

Gly	Gly	Ser	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Gln	Val		
				115			120				125				

Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ser Ser Val
 130 135 140

Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Tyr Trp Met
 145 150 155 160

Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Gln
 165 170 175

Ile Trp Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys Gly
 180 185 190

Lys Ala Thr Leu Thr Ala Asp Glu Ser Ser Ser Thr Ala Tyr Met Gln
 195 200 205

Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg
 210 215 220

Arg Glu Thr Thr Val Gly Arg Tyr Tyr Tyr Ala Met Asp Tyr Trp
 225 230 235 240

Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 245 250

<210> 50

<211> 720

<212> DNA

<213> artificial sequence

<220>

<223> CD3 VL/VH nuc

<400> 50	
gacattcagc tgaccaggc tccagcaatc atgtctgcat ctccagggga gaaggtcacc	60
atgacctgca gagccaggcc aagtgttaatc tacatgaact ggtaccagca gaagtcaggc	120
acctccccca aaagatggat ttatgacaca tccaaagtgg cttctggagt cccttatcgc	180
ttcagtgccgca gtgggtctgg gacctcatac tctctcacaa tcagcagcat ggaggctgaa	240
gatgctgcca cttattactg ccaacagtgg agtagtaacc cgctcacgtt cggtgctggg	300
accaagctgg agctgaaagg tgggtgggt tctggcgccg gcggctccgg tggtggtgg	360
tctgatatac aactgcagca gtcagggct gaactggcaa gacctggggc ctcagtgaag	420
atgtcctgca agacttctgg ctacaccttt actaggtaac cgtgcactg ggtaaaacag	480
aggcctggac agggctctgga atggattgga tacattaatc ctagccgtgg ttataactaat	540
tacaatcaga agttcaagga caaggccaca ttgactacag acaaattcctc cagcacagcc	600
tacatgcaac tgagcagcct gacatctgag gactctgcag tctattactg tgcaagat	660

39

tatgatgatc attactgcct tgactactgg ggc_{caaggca} ccactctcac agtctcctca 720

<210> 51

<211> 240

<212> PRT

<213> artificial sequence

<220>

<223> CD3 VL/VH aa

<400> 51

Asp	Ile	Gln	Leu	Thr	Gln	Ser	Pro	Ala	Ile	Met	Ser	Ala	Ser	Pro	Gly
1		5						10						15	

Glu	Lys	Val	Thr	Met	Thr	Cys	Arg	Ala	Ser	Ser	Ser	Val	Ser	Tyr	Met
		20					25						30		

Asn	Trp	Tyr	Gln	Gln	Lys	Ser	Gly	Thr	Ser	Pro	Lys	Arg	Trp	Ile	Tyr
35					40						45				

Asp	Thr	Ser	Lys	Val	Ala	Ser	Gly	Val	Pro	Tyr	Arg	Phe	Ser	Gly	Ser
50					55						60				

Gly	Ser	Gly	Thr	Ser	Tyr	Ser	Leu	Thr	Ile	Ser	Ser	Met	Glu	Ala	Glu
65					70					75			80		

Asp	Ala	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Trp	Ser	Ser	Asn	Pro	Leu	Thr
							85		90				95		

Phe	Gly	Ala	Gly	Thr	Lys	Leu	Glu	Leu	Lys	Gly	Gly	Gly	Ser	Gly
		100					105			110				

Gly	Gly	Gly	Ser	Gly	Gly	Gly	Ser	Asp	Ile	Lys	Leu	Gln	Gln	Ser
		115				120					125			

Gly	Ala	Glu	Leu	Ala	Arg	Pro	Gly	Ala	Ser	Val	Lys	Met	Ser	Cys	Lys
					130		135				140				

Thr	Ser	Gly	Tyr	Thr	Phe	Thr	Arg	Tyr	Thr	Met	His	Trp	Val	Lys	Gln
145					150					155			160		

Arg	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Ile	Gly	Tyr	Ile	Asn	Pro	Ser	Arg
						165			170			175			

Gly	Tyr	Thr	Asn	Tyr	Asn	Gln	Lys	Phe	Lys	Asp	Lys	Ala	Thr	Leu	Thr
						180			185			190			

Thr	Asp	Lys	Ser	Ser	Ser	Thr	Ala	Tyr	Met	Gln	Leu	Ser	Ser	Leu	Thr
							195		200			205			

40

Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Tyr Tyr Asp Asp His
210 215 220

Tyr Cys Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser
225 230 235 240

<210> 52

<211> 10

<212> PRT

<213> artificial sequence

<220>

<223> CD3 CDR-H1

<400> 52

Gly Tyr Thr Phe Thr Arg Tyr Thr Met His
1 5 10

<210> 53

<211> 16

<212> PRT

<213> artificial sequence

<220>

<223> CD3 CDR-H2

<400> 53

Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Val Lys
1 5 10 15

<210> 54

<211> 10

<212> PRT

<213> artificial sequence

<220>

<223> CD3 CDR-H3

<400> 54

Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr
1 5 10

<210> 55
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> CD3 CDR-L1
<400> 55

Arg Ala Ser Ser Ser Val Ser Tyr Met Asn
1 5 10

<210> 56
<211> 7
<212> PRT
<213> artificial sequence

<220>
<223> CD3 CDR-L2
<400> 56

Asp Thr Ser Lys Val Ala Ser
1 5

<210> 57
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> CD3 CDR-L3
<400> 57

Gln Gln Trp Ser Ser Asn Pro Leu Thr
1 5

<210> 58
<211> 10
<212> PRT
<213> artificial sequence

<220>

<223> anti-CD19 CDR-H1

<400> 58

Gly Tyr Ala Phe Ser Ser Tyr Trp Met Asn
1 5 10

<210> 59

<211> 17

<212> PRT

<213> artificial sequence

<220>

<223> anti-CD19 CDR-H2

<400> 59

Gln Ile Trp Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys
1 5 10 15

Gly

<210> 60

<211> 15

<212> PRT

<213> artificial sequence

<220>

<223> anti-CD19 CDR-H3

<400> 60

Arg Glu Thr Thr Thr Val Gly Arg Tyr Tyr Tyr Ala Met Asp Tyr
1 5 10 15

<210> 61

<211> 15

<212> PRT

<213> artificial sequence

<220>

<223> anti-CD19 CDR-L1

<400> 61

Lys Ala Ser Gln Ser Val Asp Tyr Asp Gly Asp Ser Tyr Leu Asn
1 5 10 15

<210> 62

<211> 7

<212> PRT

<213> artificial sequence

<220>

<223> anti-CD19 CDR-L2

<400> 62

Asp Ala Ser Asn Leu Val Ser
1 5

<210> 63

<211> 9

<212> PRT

<213> artificial sequence

<220>

<223> anti-CD19 CDR-L3

<400> 63

Gln Gln Ser Thr Glu Asp Pro Trp Thr
1 5

<210> 64

<211> 372

<212> DNA

<213> artificial sequence

<220>

<223> anti-CD19 VH nuc

<400> 64

caggtgcagc tgcagcagtc tggggctgag ctgggtgaggc ctgggtcctc agtgaagatt 60

tcctgcaagg cttctggcta tgcattcagt agctactgga tgaactgggt gaagcagagg 120

cctggacagg gtcttgagtg gattggacag atttggcctg gagatggta tactaactac 180

aatggaaagt tcaagggtaa agccactctg actgcagacg aatcctccag cacagcctac 240

44

atgcaactca gcagccttagc atctgaggac tctgcggtct atttctgtgc aagacggag 300
 actacgacgg taggccgtta ttactatgct atggactact gggccaagg gaccacggtc 360
 accgtctcct cc 372.

<210> 65

<211> 124

<212> PRT

<213> artificial sequence

<220>

<223> anti-CD19 VH aa

<400> 65

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ser
 1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Tyr
 20 25 30

Trp Met Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45

Gly Gln Ile Trp Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe
 50 55 60

Lys Gly Lys Ala Thr Leu Thr Ala Asp Glu Ser Ser Ser Thr Ala Tyr
 65 70 75 80

Met Gln Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Phe Cys
 85 90 95

Ala Arg Arg Glu Thr Thr Val Gly Arg Tyr Tyr Tyr Ala Met Asp
 100 105 110

Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120

<210> 66

<211> 333

<212> DNA

<213> artificial sequence

<220>

<223> anti-CD19 VL nuc

<400> 66
 gatatccagc tgacccagtc tccagcttct ttggctgtgt ctctaggca gagggccacc 60
 atctcctgca aggccagcca aagtgttgat tatgatggtg atagttattt gaactggcac
 caacagattc caggacagcc acccaaactc ctcatctatg atgcatccaa tctagttct 120
 gggatcccac ccaggttag tggcagtggg tctgggacag acttcaccct caacatccat 180
 cctgtggaga aggtggatgc tgcaacctat cactgtcagc aaagtactga ggatccgtgg 240
 acgttcggtg gagggaccaa gctcgagatc aaa 300
 333

<210> 67

<211> 111

<212> PRT

<213> artificial sequence

<220>

<223> anti-CD19 VL aa

<400> 67

Asp	Ile	Gln	Leu	Thr	Gln	Ser	Pro	Ala	Ser	Leu	Ala	Val	Ser	Leu	Gly
1				5				10					15		

Gln	Arg	Ala	Thr	Ile	Ser	Cys	Lys	Ala	Ser	Gln	Ser	Val	Asp	Tyr	Asp
	20				25							30			

Gly	Asp	Ser	Tyr	Leu	Asn	Trp	Tyr	Gln	Gln	Ile	Pro	Gly	Gln	Pro	Pro
	35				40						45				

Lys	Leu	Leu	Ile	Tyr	Asp	Ala	Ser	Asn	Leu	Val	Ser	Gly	Ile	Pro	Pro
	50				55					60					

Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Asn	Ile	His
65			70					75					80		

Pro	Val	Glu	Lys	Val	Asp	Ala	Ala	Thr	Tyr	His	Cys	Gln	Gln	Ser	Thr
	85				90					95					

Glu	Asp	Pro	Trp	Thr	Phe	Gly	Gly	Thr	Lys	Leu	Glu	Ile	Lys		
	100				105						110				

<210> 68

<211> 45

<212> DNA

<213> artificial sequence

46

<220>

<223> standard linker (G4S)3 nuc

<400> 68

ggtgtgttg gttctggcgg cggcggtcc ggtgggtggt gttct

45

<210> 69

<211> 15

<212> PRT

<213> artificial sequence

<220>

<223> standard linker (G4S)3 aa

<400> 69

Gly Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser
1 5 10 15

<210> 70

<211> 15

<212> DNA

<213> artificial sequence

<220>

<223> standard spacer (G4S)1 nuc

<400> 70

ggaggtggtg gatcc

15

<210> 71

<211> 5

<212> PRT

<213> artificial sequence

<220>

<223> standard linker (G4S)1 aa

<400> 71

Gly Gly Gly Gly Ser
1 5

<210> 72

<211> 10

<212> PRT

<213> artificial sequence

<220>

<223> CDR-L1 anti-CD3

<400> 72

Ser Ala Ser Ser Ser Val Ser Tyr Met Asn
1 5 10

<210> 73

<211> 7

<212> PRT

<213> artificial sequence

<220>

<223> CDR-L2 anti-CD3

<400> 73

Asp Thr Ser Lys Leu Ala Ser
1 5

<210> 74

<211> 9

<212> PRT

<213> artificial sequence

<220>

<223> CDR-L3 anti-CD3

<400> 74

Gln Gln Trp Ser Ser Asn Pro Phe Thr
1 5

<210> 75

<211> 10

<212> PRT

<213> artificial sequence

<220>

48

<223> CDR-H1 anti-CD3

<400> 75

Gly Tyr Lys Phe Ser Ser Ser Val Met His
1 5 10

<210> 76

<211> 17

<212> PRT

<213> artificial sequence

<220>

<223> CDR-H2 anti-CD3

<400> 76

Tyr Ile Asn Pro Tyr Asn Asp Val Thr Lys Tyr Thr Glu Lys Phe Lys
1 5 10 15

Gly

<210> 77

<211> 11

<212> PRT

<213> artificial sequence

<220>

<223> CDR-H3 anti-CD3

<400> 77

Ser Pro Tyr Tyr Asp Tyr Asp Gly Phe Ala Tyr
1 5 10

<210> 78

<211> 393

<212> DNA

<213> artificial sequence

<220>

<223> CD3-epsilon extracellular domain with leader - nuc

<400> 78

atgggatgga gctgttatcat cctcttcttg gtagcaacag ctacagggtgt acactccgat

60

49

ggtaatgaag aaatgggtgg tattacacag acaccatata aagtctccat ctctggaacc 120
 acagtaatat tgacatgccc tcagtatcct ggatctgaaa tactatggca acacaatgat 180
 aaaaacatag gcggtgatga ggatgataaa aacataggca gtgatgagga tcacctgtca 240
 ctgaaggaat tttcagaatt ggagcaaagt ggttattatg tctgctaccc cagaggaagc 300
 aaaccagaag atgcgaactt ttatctctac ctgagggcaa gagtgtgtga gaactgcatt 360
 gagatggatt ccgggcatca tcaccatcat cat 393

<210> 79

<211> 131

<212> PRT

<213> artificial sequence

<220>

<223> CD3-epsilon extracellular domain with leader - aa

<400> 79

Met	Gly	Trp	Ser	Cys	Ile	Ile	Leu	Phe	Leu	Val	Ala	Thr	Ala	Thr	Gly
1				5					10				15		

val	His	Ser	Asp	Gly	Asn	Glu	Glu	Met	Gly	Gly	Ile	Thr	Gln	Thr	Pro
								20			25		30		

Tyr	Lys	val	Ser	Ile	Ser	Gly	Thr	Thr	val	Ile	Leu	Thr	Cys	Pro	Gln
							35			40		45			

Tyr	Pro	Gly	Ser	Glu	Ile	Leu	Trp	Gln	His	Asn	Asp	Lys	Asn	Ile	Gly
					55				60						

Gly	Asp	Glu	Asp	Asp	Lys	Asn	Ile	Gly	Ser	Asp	Glu	Asp	His	Leu	Ser
65					70				75				80		

Leu	Lys	Glu	Phe	Ser	Glu	Leu	Glu	Gln	Ser	Gly	Tyr	Tyr	val	Cys	Tyr
								85			90		95		

Pro	Arg	Gly	Ser	Lys	Pro	Glu	Asp	Ala	Asn	Phe	Tyr	Leu	Tyr	Leu	Arg
							100		105			110			

Ala	Arg	Val	Cys	Glu	Asn	Cys	Met	Glu	Met	Asp	Ser	Gly	His	His	His
							115		120			125			

His	His	His													
			130												

<210> 80

<211> 36

50

<212> DNA

<213> artificial sequence

<220>

<223> 5' BsrGI primer

<400> 80

aggtgtacac tccgatggta atgaagaaat gggtgg

36

<210> 81

<211> 42

<212> DNA

<213> artificial sequence

<220>

<223> 3' BspEI primer

<400> 81

cgatccggaa tccatctcca tgcagttctc acacactctt gc

42

<210> 82

<211> 146

<212> DNA

<213> artificial sequence

<220>

<223> mouse Ig leader and cloning site

<400> 82

gaattcacca tggatggag ctgtatcatc ctcttcttgg tagcaacagc tacaggtgta

60

cactccgata tcaagcttcc ggacgctccc gactcaagcg cccgtgccac acagccgcaa

120

gatctggcgc cgtgtggtca gtcgac

146

**INTERNATIONAL SEARCH REPORT
CORRECTED VERSION**

International Application No.

PCT/EP2004/005685

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K16/28 A61K39/395 A61P35/00 A61P35/02 A61P19/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 1 293 514 A (AFFIMED THERAPEUTICS AG) 19 March 2003 (2003-03-19) figures 4,6a -----	1-20,22, 25 21,23,24
Y	WO 99/54440 A (RIETHMUELLER GERT ; BARGOU RALF (DE); DOERKEN BERND (DE); KUFER PETER) 28 October 1999 (1999-10-28) claims 24,25 ----- -/-	21,23,24

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

5 November 2004

Date of mailing of the international search report

12.11.2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Wagner, R

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/EP2004/005685

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, A	KIPRIYANOV S M ET AL: "Effect of Domain Order on the Activity of Bacterially Produced Bispecific Single-chain Fv Antibodies" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 330, no. 1, 27 June 2003 (2003-06-27), pages 99-111, XP004445110 ISSN: 0022-2836 the whole document	1-25
A	KIPRIYANOV S M ET AL: "Bispecific tandem diabody for tumour therapy with improved antigen binding and pharmacokinetics" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 293, 1999, pages 41-56, XP004457324 ISSN: 0022-2836 the whole document	1-25
A	LOEFFLER A ET AL: "Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct." LEUKEMIA (BASINGSTOKE), vol. 17, no. 5, May 2003 (2003-05), pages 900-909, XP002299902 ISSN: 0887-6924 the whole document	1-25
A	DREIER TORSTEN ET AL: "T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct." JOURNAL OF IMMUNOLOGY, vol. 170, no. 8, 15 April 2003 (2003-04-15), pages 4397-4402, XP002299903 ISSN: 0022-1767 the whole document	1-25
A	LOEFFLER ANJA ET AL: "A recombinant bispecific single-chain antibody, CD19 X CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes" BLOOD, vol. 95, no. 6, 15 March 2000 (2000-03-15), pages 2098-2103, XP002299904 ISSN: 0006-4971 the whole document	1-25

-/-

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/EP2004/005685

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KIPRIYANOV S M ET AL: "Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells" INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 77, no. 5, 31 August 1998 (1998-08-31), pages 763-771, XP002115487 ISSN: 0020-7136 the whole document -----	1-25

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2004/005685

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 19–21 because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 19–21 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest


- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP2004/005685

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
EP 1293514	A	19-03-2003	EP	1293514 A1		19-03-2003
			WO	03025018 A2		27-03-2003
WO 9954440	A	28-10-1999	AT	244758 T		15-07-2003
			AU	761587 B2		05-06-2003
			AU	4135299 A		08-11-1999
			BG	104868 A		28-09-2001
			BR	9909860 A		19-12-2000
			CA	2326389 A1		28-10-1999
			CN	1299410 T		13-06-2001
			DE	69909459 D1		14-08-2003
			DE	69909459 T2		27-05-2004
			DK	1071752 T3		20-10-2003
			WO	9954440 A1		28-10-1999
			EP	1348715 A2		01-10-2003
			EP	1071752 A1		31-01-2001
			ES	2203141 T3		01-04-2004
			HR	20000714 A1		31-12-2001
			HU	0102535 A2		28-10-2001
			ID	27512 A		12-04-2001
			JP	2002512020 T		23-04-2002
			NO	20005296 A		13-12-2000
			NZ	507381 A		19-12-2003
			PL	344016 A1		24-09-2001
			PT	1071752 T		28-11-2003
			RU	2228202 C2		10-05-2004
			SI	1071752 T1		31-12-2003
			SK	15792000 A3		10-05-2001
			TR	200003087 T2		21-02-2001
			ZA	200005866 A		18-04-2001



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record.**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.